TRIM34 restricts HIV-1 and SIV capsids in a TRIM5α-dependent manner

Molly Ohainle; Kyusik Kim; Sevnur Komurlu Keceli; Abby Felton; Ed Campbell; Jeremy Luban; Michael Emerman

doi:10.1371/journal.ppat.1008507

. 2020 Apr 13;16(4):e1008507. doi: 10.1371/journal.ppat.1008507

TRIM34 restricts HIV-1 and SIV capsids in a TRIM5α-dependent manner

Molly Ohainle ^1,^*, Kyusik Kim ^2,^#, Sevnur Komurlu Keceli ^3,^#, Abby Felton ¹, Ed Campbell ³, Jeremy Luban ², Michael Emerman ^1,^*

Editor: David T Evans⁴

PMCID: PMC7179944 PMID: 32282853

Abstract

The HIV-1 capsid protein makes up the core of the virion and plays a critical role in early steps of HIV replication. Due to its exposure in the cytoplasm after entry, HIV capsid is a target for host cell factors that act directly to block infection such as TRIM5α and MxB. Several host proteins also play a role in facilitating infection, including in the protection of HIV-1 capsid from recognition by host cell restriction factors. Through an unbiased screening approach, called HIV-CRISPR, we show that the CPSF6-binding deficient, N74D HIV-1 capsid mutant is sensitive to restriction mediated by human TRIM34, a close paralog of the well-characterized HIV restriction factor TRIM5α. This restriction occurs at the step of reverse transcription, is independent of interferon stimulation, and limits HIV-1 infection in key target cells of HIV infection including CD4+ T cells and monocyte-derived dendritic cells. TRIM34 can also restrict some SIV capsids. TRIM34 restriction requires TRIM5α as knockout or knockdown of TRIM5α results in a loss of antiviral activity. Through immunofluorescence studies, we show that TRIM34 and TRIM5α colocalize to cytoplasmic bodies and are more frequently observed to be associated with infecting N74D capsids than with WT HIV-1 capsids. Our results identify TRIM34 as an HIV-1 CA-targeting restriction factor and highlight the potential role for heteromultimeric TRIM interactions in contributing to restriction of HIV-1 infection in human cells.

Author summary

HIV-1 infection in humans is the result of cross-species transmission of a related primate lentivirus from chimpanzees. In order to adapt to replicate in human cells, HIV-1 adapted to host proteins that restrict infection by viruses. The HIV-1 capsid protein encapsidates the HIV-1 genome, allowing it to be delivered to the host cell for integration into the host chromosome. However, on delivery to the cytoplasm the HIV-1 capsid protein is exposed to an array of capsid-targeting restriction factors that act to limit infection. Viral mutants can be used to reveal some of these restriction factors. Our results show that TRIM34 is an antiviral effector that blocks infection of an HIV with a particular mutation in capsid. TRIM34 also inhibits some lentiviruses that infect monkeys. This block requires the closely-related paralog TRIM5α, a capsid-targeting restriction factor with well-characterized antiviral activity in primates. These results highlight the complex interaction between HIV-1 with human antiviral proteins.

Introduction

The HIV-1 capsid protein (CA or p24^gag) forms the core of the virion and is key to effective delivery of the HIV-1 genome inside a host cell and into the nucleus where integration into the host chromosome occurs [1, 2]. HIV-1 CA is involved in the early steps of HIV-1 replication including uncoating, nuclear entry, and integration site selection [1–4]. HIV-1 CA is also an important target for host restriction factors such as rhesus TRIM5α (the alpha isoform of the TRIM5 gene) and MXB (reviewed in [1, 5]).

Many restriction factors are induced by type I Interferon (IFN). Although Human TRIM5α, previously thought to lack significant activity against primate lentiviruses, has recently been shown to restrict wild type (WT) HIV-1 capsids in IFN-treated cells [6, 7]. TRIM5α restriction of retroviral capsids is driven by interactions between the C-terminal SPRY domain of TRIM5α and determinants present in assembled CA structures [8]. While the affinity of the SPRY domain for CA is low, this low affinity is overcome by TRIM5α dimerization and its ability to form higher-order assemblies around the viral core, enhancing avidity of the TRIM5α-CA interaction [8]. TRIM5α is also able to oligomerize with other TRIM-family members [9, 10]. One key aspect of TRIM biology that remains relatively unexplored includes the potential for hetero-oligomerization of TRIM proteins that could have important functional consequences.

Through the study of HIV-1 CA mutants that lack binding to host cell factors or possess other key phenotypes, such as altered stability, much has been revealed about how CA determines the fate of HIV-1 cores inside cells. For example, the host proteins CPSF6 and Cyclophilin A (CypA) have a complex but important role in HIV-1 CA interactions and infection [1]. HIV-1 CA binds CypA which provides protection against the action of TRIM5α [11, 12]. CPSF6 interacts with HIV-1 capsid on entry into target cells [13, 14] and facilitates interaction with nuclear import pathways that enhances targeting of HIV-1 integration into gene-rich regions [15, 16]. Single amino acid mutations in the HIV-1 capsid protein, for example N74D for CPSF6 and P90A for CypA, abrogate binding to these host factors [13, 17]. Both capsid mutants have been demonstrated to infect cells less efficiently than wild type (WT) in some cell types, including primary cell such as CD4+ T cells and monocyte-derived macrophages (MDMs) [12, 17–19]. Further, both the HIV-1 P90A capsid mutant and the HIV-1 N74D capsid mutant, referred to hereafter as P90A and N74D respectively, have been shown to be hypersensitive to the effects of IFN [19], suggesting that one or more IFN-induced restriction factors block infection of these capsid mutant viruses. Restriction of these mutants has been shown to be independent of the IFN-induced capsid-targeting restriction factor MxB [19] but identification of other capsid-targeting restriction factors underlying the increased IFN sensitivity of these CA mutants has been elusive.

Previously, we demonstrated that human genes that mediate the antiviral effects of IFN can be identified through an unbiased CRISPR screening approach called HIV-CRISPR [6]. Here we use this approach to identify capsid-targeting restrictions that target the P90A and N74D HIV-1 capsid mutants. While the CypA-binding deficient P90A mutant becomes more sensitive to TRIM5α restriction, the CPSF6-binding deficient N74D mutant becomes sensitive to a novel restriction by the TRIM5α paralog, TRIM34. This restriction is independent of IFN induction as well as CPSF6 binding and results in a block during HIV reverse transcription. TRIM34 restriction occurs in primary cells in addition to the THP-1 monocytic cell line used in our screens. Further, we find that TRIM34 requires TRIM5α to inhibit N74D while inhibition of P90A occurs independent of TRIM34. Thus, we find that TRIM34 is a novel inhibitor of HIV-1 and SIV capsids that acts in conjunction with TRIM5α to limit infection of primary T cells.

Results

HIV-CRISPR screening identifies TRIM34 as an inhibitor of the HIV-1 N74D capsid mutant

P90A and N74D have been shown to be impaired in replication both in IFN-treated and untreated cells [17–20]. Therefore, we hypothesized that the P90A (CypA-deficient) and N74D (CPSF6-deficient) capsid mutants may be more sensitive to inhibition by capsid-targeting restriction factors in human cells. Two possible outcomes are that these mutants are either more sensitive to the same restrictions that target wild type capsids or that they are sensitive to novel capsid-targeting restriction factor(s).

To identify the host cell restrictions targeting these capsid mutant viruses, we used our unbiased screening approach, HIV-CRISPR screening, to ask what genes in our library of ~2000 genes enriched in Interferon-Stimulated Genes (ISGs) [6] are responsible for inhibiting both mutants in THP-1 cells. HIV-CRISPR screening is a virus-packageable CRISPR screening approach in which infecting HIV virions package the HIV-CRISPR modified lentiviral vector in trans upon budding from the infected cell [6]. As the level of virus replication is dependent on the phenotype of gene knockout introduced by Cas9 endonuclease and sgRNA encoded in the HIV-CRISPR vector, the virus itself serves to readout the barcodes of gene knockouts with effects on virus replication (Fig 1A). Quantification of individual 20bp sgRNA sequences enriched in the virions relative to the representation of sgRNA sequences in the cell populations allows for the identification of antiviral genes as gene knockouts that allow for more robust replication of each virus. In the HIV-CRISPR screens described here, a library of cells transduced with the HIV-CRISPR vector targeting genes enriched in ISGs, the PIKA_HIV library [6], was infected with WT, N74D or P90A viruses after overnight treatment with IFN alpha.

Cell pellets and viral supernatants were collected and both genomic DNA from cells and viral RNA from virions were isolated and amplified for deep sequencing and MAGeCK analysis [21] to identify sgRNA sequences significantly enriched in the viral supernatant of each virus (Fig 1B: WT vs P90A; Fig 1C: WT vs N74D; see S1 Table for full screen results). The four genes in the library that are essential for IFN signaling, STAT1, STAT2, IFNAR1 and IRF9, were the highest-scoring hits in both screens as knockout of any gene in this pathway results in rescue of IFN inhibition of viral replication (Fig 1B and 1C: magenta). Next, a core set of ISGs, including MXB (MX2), IFITM1, TETHERIN (BST2) and TRIM5, were some of the highest-scoring gene hits for all three viruses screened (WT, N74D and P90A viruses). Therefore, these restriction factors target the capsid mutants similar to what we previously found for wild type HIV-1 [6] and as we observed again here (Fig 1B and 1C: cyan, yellow and dark blue, respectively). In both capsid mutant screens we measured a lower rank for MXB than for WT (Fig 1B and 1C–compare rank in WT screen as compared to either capsid mutant), consistent with the previously-reported relative resistance of both P90A and N74D to restriction by MXB [19, 22–27]. In contrast, TRIM5 is the highest-scoring gene hit for P90A (Fig 1B: yellow). This is consistent with recent results showing that loss of CypA binding by HIV-1 capsids results in sensitivity to TRIM5α restriction [12].

For the N74D screen, we find a novel HIV-1 restriction factor gene, TRIM34, as the highest-scoring hit that is not found in the screen with WT HIV-1 (Fig 1C: Green). TRIM34 scores as highly as the IFN pathway genes (Fig 1C: Magenta), highlighting the key role TRIM34 potentially plays in blocking replication of the N74D capsid mutant virus. We also find TRIM34 as a less significant hit in the P90A screen as compared to the N74D screen, suggesting it may have a minor role in restriction of the P90A virus at least in some cell types (Fig 1B). TRIM34 was first described to be an Interferon-Stimulated Gene in HeLa cells [28] and is in a cluster of paralogous human TRIM genes that includes TRIM5, TRIM22 and TRIM6 on human chromosome 11 [29]. Like all members of the TRIM gene family [8], TRIM34 encodes an N-terminal RBCC or tripartite motif, including RING, B-Box and coiled-coil domains (Fig 1D) [28]. TRIM34 shares 56% amino acid identity and overall domain structure with the closely-related, capsid-targeting HIV-1 restriction factor TRIM5α (Fig 1D). Therefore, TRIM34 could share some functional features of TRIM5α biology. However, unlike TRIM5α, TRIM34 has some surprising features. First, TRIM34 is not a significantly rapidly-evolving gene in primates [29, 30]. Positive selection is frequently a feature of host antiviral genes in longstanding conflict with pathogens; therefore, the lack of positive selection in TRIM34 is unexpected. Further, human TRIM34 has a deletion in the v1 region of the B30.2 PRY/SPRY domain (Fig 1D). The v1 loop of the TRIM5α SPRY domain contains multiple sites of positive selection in primate TRIM5 and is known to be important for determining the specificity of capsid recognition by TRIM5α [31]. These findings suggest that while TRIM34 may have some structural and functional homology with TRIM5α, TRIM34 restriction of this HIV mutant is also likely to differ in some ways from TRIM5α.

TRIM34 inhibits N74D at a step before completion of reverse transcription

To validate the screen results (Fig 1) which suggest that TRIM34 restricts N74D but not WT HIV-1, we knocked out TRIM34 in THP-1 cells by transduction with a lentiviral vector encoding Cas9 and two different TRIM34-specific sgRNAs together with Non-Targeting Control (NTC) sgRNAs (Fig 2A and 2B). Efficient TRIM34 gene knockout was confirmed by sequencing analysis of the TRIM34 locus in both populations of cells (Fig 2A and 2B–63% edited alleles for TRIM34KO_1 and 83% edited alleles for TRIM34KO_2). Control and TRIM34-KO cell populations were then infected with both WT and N74D viruses after overnight IFN treatment and the % infected cells was assayed by flow cytometry. We observed no significant effect of TRIM34 knockout on the replication of the WT virus (Fig 2A; P>0.05). In contrast, we observe 2.2-fold rescue of N74D replication across both TRIM34 KO pools (Fig 2A; P<0.001), consistent with our HIV-CRISPR screen results that found TRIM34 as a block to N74D infection in THP-1 cells.

Fig 2 — A and B: THP-1 cells were transduced with a lentiviral vector encoding Cas9 and an sgRNA targeting either TRIM34 (Gray Bars: n = 2 pools, each an independent sgRNA) or a Non-Targeting Control (NTC) sgRNA (White Bars: n = 2 pools, each an independent sgRNA). TRIM34 KO in each cell pool was determined by ICE Analysis (TRIM34-KO_1 = 63% ICE KO-Score, TRIM34_2 = 83% ICE KO-Score). Edited cells were infected with either WT or N74D HIV and the amount of HIV replication assayed by analysis of GFP+ cells 2 days post-infection after overnight IFN treatment (A) or in untreated cells (no IFN) (B). P values were calculated by combining all replicates from triplicate infections in both edited populations for either the NTC control or TRIM34 KO. The fold increase in infection in the TRIM34-KO cells as compared to the NTC cells is shown for each virus in each condition. Data are represented as the mean +/- s.d. C: An HIV-CRISPR screen (with the ISG-enriched PIKA_HIV library) was performed with a single replicate in THP-1 cells without any IFN treatment for the N74D capsid mutant virus. MAGeCK Gene Scores (-log₁₀MAGeCK Gene Scores) for the Top 10 gene hits are shown. Black bar: TRIM34. Gray bar: Non-Targeting Control (NTC). White bars: other gene hits. D: Primary, activated CD4+ T cells were electroporated with Cas9-RNP complexes targeting TRIM34 (gray bars) or control complexes (white bars: control). TRIM34 KO in this pool was determined to be edited at 54% (ICE KO-Score). 2 days post-electroporation edited CD4+ T cell pools were infected with GFP reporter HIV-1 viruses (WT or N74D) and infection levels assayed 2 days later by flow cytometry. Data are represented as the mean +/- s.d. from triplicate infections. E: THP-1 cells were transduced with a lentiviral vector (pHIV-dTomato) encoding TRIM34 (gray bars) or empty vector (white bars: control). Cell populations were sorted for dTomato expression and, following recovery, were infected with VSV-G pseudotyped WT or N74D Luciferase reporter viruses (HIV-1_LAI CA-WT LUC or HIV-1_LAI CA-N74D LUC). Two days later levels of infection were assayed through a Luciferase Assay. Data are represented as the mean +/- s.d. from duplicate infections. F: TRIM34-overexpressing cells (gray bars) or control cells (white bars) were infected with VSV/G-pseudotyped HIV-1_LAI CA-WT LUC or HIV-1_LAI CA-N74D LUC viruses with or without Nevirapine (NVP) to inhibit HIV reverse transcription. 16 hours later viral cDNA was collected and levels of HIV reverse transcription products were assayed by qPCR. Data are represented as the mean +/- s.d. from triplicate (no NVP) or duplicate (+NVP) infections. P values were determined using two-sided unpaired t-tests (ns = not significant, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).

To ask if TRIM34 restriction occurs only in IFN-treated cells as has recently been shown for TRIM5α [7], we also infected control and TRIM34-KO cells with WT and N74D virus without any IFN treatment and assayed the % infected cells by flow cytometry (Fig 2B). Unlike TRIM5α inhibition of wild type HIV-1 capsids [7], TRIM34 is a constitutive inhibitor of the N74D CA mutant as KO rescues infection of the N74D virus even in the absence of IFN treatment 2.0-Fold (Fig 2B; P<0.001). Further confirming these findings, we repeated the HIV-CRISPR screen in THP-1 cells without any IFN treatment and still find TRIM34 as a hit that is specific to the HIV-1 N74D virus as TRIM34 is the 2^nd highest ranked gene in this screen without IFN (Fig 2C–black bar). Importantly, while we initially identified TRIM34 in a screen for IFN-induced genes that block the N74D virus, these data suggest that TRIM34 is actually a constitutive block to infection whose activity is IFN-independent. Therefore, subsequent experiments are performed in the absence of IFN.

We also determined whether or not TRIM34 plays a role in restriction of HIV-1 capsids in primary activated, CD4+ T cells. TRIM34 KO CD4+ T cell pools were generated through electroporation of CD3/CD28-activated, CD4+ T cells with CRISPR/Cas9 complexes targeting TRIM34 or Non-Targeting Control complexes. 54% of TRIM34 alleles were found to be edited in this experiment (ICE KO-Score). We infected the control and TRIM34-KO pools with both WT and N74D viruses and measured infection levels after 2 days by flow cytometry. We do not observe any rescue of WT infection on knockout of TRIM34 (Fig 2D; ns). However, knockout of TRIM34 in primary CD4+ T cells has an 8-fold effect which is an even stronger effect on N74D than what we observed in THP-1 cells (Fig 2D; P<0.01, compare with Fig 2A). Therefore, endogenously-expressed TRIM34 is a constitutive HIV-1 restriction factor in these key HIV-1 target cells.

TRIM5α binds to and blocks HIV-1 capsids in the cytoplasm, resulting in significantly decreased reverse transcription products during infection [8]. Moreover, there is a block prior to reverse transcription of the N74D CPSF6-binding capsid mutant in macrophages [18]. Thus, we hypothesized that TRIM34 would mediate a similar block before reverse transcription would occur. In order to test this hypothesis, we stably-overexpressed human TRIM34 in clonal TRIM34-KO THP-1 cells and assayed replication of both the wild type and the N74D CA mutant viruses. TRIM34 overexpression does not result in any significant inhibition of WT HIV-1 (Fig 2E, left panel). In contrast, we observe significant inhibition of the N74D mutant by TRIM34 (Fig 2E, right panel). Therefore, as predicted for a restriction factor, overexpression of TRIM34 in THP-1 inhibits infection of cells by the HIV-1 N74D CA mutant virus. To ask if TRIM34 blocks infection before reverse transcription, similar to rhesus TRIM5α, we infected control and TRIM34-overexpressing THP-1 cells and assayed viral DNA accumulation through a qPCR assay that detects HIV-1 reverse transcription products [32]. Infections in the presence of Nevirapine (NVP) were performed in parallel to determine background levels of DNA from viral stocks (Fig 2F). The inhibition of replication of the HIV-1 N74D CA virus (Fig 2E) in TRIM34-overexpressing cells is correlated with a similar decrease in the accumulation of HIV viral DNA (Fig 2F). Therefore, TRIM34, like its paralog TRIM5α, inhibits HIV-1 replication early in the viral life cycle before the completion of reverse transcription.

TRIM34 restricts HIV-1 and SIV capsids independent of CPSF6 binding

The N74D CA mutant virus was first characterized due to its loss of CPSF6 binding [13]. Therefore, we reasoned that loss of CPSF6 binding could expose HIV-1 CA to restriction by TRIM34. To ask if the loss of CPSF6 binding is sufficient to sensitize HIV-1 capsids to TRIM34 restriction, we tested another CPSF6-binding capsid mutant HIV-1 A77V that, like HIV-1 N74D, also results in loss of binding to CPSF6 [33]. In contrast to infection with HIV-1 N74D CA, we find that infection of TRIM34-overexpressing cells is equivalent to WT cells for the HIV-1 A77V mutant (Fig 3A). We further tested the relative sensitivity of HIV-1 N74D and HIV-1 A77V in primary cells by knocking out TRIM34 in primary CD4+ T cells (Fig 3B–TRIM34-KO 52% ICE KO-score). We measured infection of these TRIM34-KO cells by the HIV-1 N74D and HIV-1 A77V CA mutants as compared to a WT HIV-1 control (Fig 3B). As shown in Fig 2, infection with the N74D CA mutant can be rescued by TRIM34 knockout in CD4+ T cells (Fig 3B). Consistent with our overexpression assay in THP-1 cells we find that the HIV-1 A77V mutant is not rescued by TRIM34 knockout in CD4+ T cells (Fig 3B). Therefore, in both THP-1 cells and primary CD4+ T cells the HIV-1 A77V mutant that lacks binding to CPSF6 does not become sensitive to TRIM34 restriction. To further explore the CPSF6-independence of TRIM34 restriction, we also assayed replication of another CPSF6-binding deficient mutant, N57A, in our ectopic overexpression system. In contrast to the restriction of the N74D capsid mutant virus measured in TRIM34-overexpressing cells, we do not observe any restriction of the N57A capsid mutant (Fig 3C). Therefore, restriction by TRIM34 is independent of CPSF6 binding status of the HIV-1 capsid. Instead restriction of the HIV-1 N74D CA by TRIM34 is determined by a feature of this capsid other than CPSF6 binding.

Fig 3 — A: THP-1 cells stably-overexpressing TRIM34 (gray bars) or control cells (white bars) were infected with WT, N74D or A77V HIV-1 and levels of infection assayed 2 days post-infection by flow cytometry. The relative infection is normalized to the average infection in the control cells for each virus. Data are represented as the mean+/- s.d. from triplicate infections. B: Primary, activated CD4+ T cells were electroporated with Cas9-RNP complexes targeting TRIM34 (gray bars: TRIM34-KO) or Non-Targeting Control crRNAs (white bars: NTC). 2 days later edited CD4+ T cell pools were infected with GFP reporter HIV viruses (WT, N74D or A77V) and infection levels assayed 2 days later by flow cytometry. Data is shown as infection levels relative to the Non-Targeting Control infections for each virus (relative infection). TRIM34-KO pool edited at 52% (ICE KO-score). Data are represented as the mean +/- s.d. from triplicate infections. C: THP-1 cells stably-overexpressing TRIM34 (gray bars) or control cells (white bars) were infected with WT, N74D or N57A HIV-1 and levels of infection assayed 2 days post-infection by flow cytometry. The relative infection is normalized to the average infection in the control cells for each virus. Data are represented as the mean+/- s.d. from triplicate infections. D and E: THP-1 cells were transduced with lentiviral vectors encoding rhesus TRIM5α (gray diamonds), human TRIM5α (gray circles), human TRIM34 (black squares) or a control vector (white squares). Each cell pool was infected with VSV-G pseudotyped SIVmacLUC (D) or SIVagmLUC (E) Luciferase reporter viruses at 3 viral doses as indicated. Levels of infectivity were assayed 2 days later by luciferase assay (RLU = Relative Luciferase Units). Data are represented as the mean +/- s.d. from triplicate infections. F and G: THP-1 cells stably-overexpressing rhesus macaque TRIM34 (mac TRIM34—gray bars) or control cells (white bars) were infected with WT (F) or N74D (G) HIV-1 and levels of infection assayed 2 days post-infection by luciferase assay. Data are represented as the mean+/- s.d. from triplicate infections. P values were determined using two-sided unpaired t-tests (ns = not significant, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).

Restriction factors from one species often potently restrict primate lentiviruses adapted to replicate in other primates to due to ongoing genetic conflict between hosts and pathogens [34]. To ask if human TRIM34 may restrict lentiviruses more broadly, including Simian Immunodeficiency Viruses (SIVs) that are adapted to infect Old World Monkeys, we assayed human TRIM34 for restriction of SIVagm and SIVmac in THP-1 cells. In contrast to human or rhesus TRIM5α, human TRIM34 overexpression inhibits replication of SIVmac significantly (Fig 3D). Similarly, replication of SIVagm is significantly blocked by human TRIM34 overexpression, although this restriction is not as potent as rhesus TRIM5α restriction of this virus (Fig 3E). Therefore, human TRIM34 retrovirus restriction activity is not limited to HIV-1 CA mutants, as TRIM34 restricts at least two SIVs in addition to the HIV-1 N74D CA mutant. Moreover, because SIVmac is restricted by TRIM34, yet is known to bind CPSF6 [13], this further supports the model that TRIM34 restriction sensitivity is not necessarily linked to CPSF6 binding of HIV or SIV capsids.

Given the lack of positive selection in TRIM34 in primates [29, 30], one might expect that TRIM34 from non-human primate could substitute for human TRIM34 in restriction of HIV-1 N74D. To test this hypothesis, we tested restriction of HIV viruses in THP-1 cells overexpressing rhesus macaque TRIM34 (mac TRIM34). While there is little effect of mac TRIM34 overexpression on wild type HIV-1 (Fig 3F), we observe significant restriction of the N74D HIV-1 virus (Fig 3G). Therefore, TRIM34 restriction is not specific to humans as TRIM34 from at least one other primate species is also capable of retroviral restriction. We do not see a species-specificity for TRIM34 restriction, consistent with the lack of positive selection signature for this gene.

TRIM34 restriction requires TRIM5α

TRIM34 is a close paralog of TRIM5α which is known to dimerize and form higher-order oligomers [8]. Furthermore, TRIM34 has been shown to be able to interact with TRIM5α in cells both in a yeast two-hybrid assay [9] as well as in immunoprecipitation studies [10, 29]. As TRIM34 lacks a signal of positive selection in the B30.2 PRY/SPRY domain [29, 30], we hypothesized that TRIM34 might require TRIM5α to restrict HIV-1 infection. This model is particularly intriguing as the PRY/SPRY domain of TRIM34 has a deletion in the v1 loop (see Fig 1D), a region shown to be critical for mediating specificity of capsid recognition by TRIM5α [31]. To test this model, we compared the ability of TRIM34 to restrict the HIV-1 N74D virus in cells both with and without TRIM5α. We introduced a TRIM5α or Control CRISPR/Cas lentiviral vector into THP-1 cells overexpressing TRIM34 (Fig 4A). Infection of these TRIM34-overexpressing, TRIM5-KO THP-1 pools demonstrates that the restriction of viral replication measured for the HIV-1 N74D capsid mutant is lost when TRIM5α is missing (Fig 4A). In contrast, we observe little effect of TRIM34 overexpression (1.2-Fold) or TRIM5-KO in THP-1 cells infected with the WT virus (Fig 4B), consistent with there being no significant restriction of HIV-1 WT capsid by either TRIM34 or TRIM5α in cells lacking IFN stimulation. Therefore, TRIM34 restriction of the HIV-1 N74D capsid mutant is dependent on TRIM5α.

Fig 4 — A and B: THP-1 cells stably-overexpressing TRIM34 (gray bars) or control cells (white bars) were transduced with sgRNA-encoding lentiviral vectors targeting TRIM5α (TRIM5KO) or a control. *TRIM5* alleles were edited at 70% for both control and TRIM34-overexpressing cells as determined by ICE analysis. Cell pools were infected with the N74D-LUC virus (A) or WT-LUC virus (B) and levels of infection assayed 2 days post-infection by luciferase assay (Relative Luciferase Units). Data are represented as the mean +/- s.d. from triplicate infections. C: Primary, activated CD4+ T cells were electroporated with Cas9-RNP complexes targeting TRIM34 (gray bars), TRIM5α (hatched, dark gray bars) or NTC crRNAs (white bars). 2 days later edited CD4+ T cell pools were infected with GFP reporter HIV-1 viruses (WT, N74D or P90A) and infection levels assayed 2 days later by flow cytometry. TRIM34-KO pools were edited at 69% and TRIM5-KO pools were edited at 87% (ICE KO-Scores). The relative infection is normalized to the average infection in the control cells for each virus. Data are represented as the mean +/- s.d. from triplicate infections. D, E and F: Monocyte-derived dendritic cells were simultaneously transduced with a lentiviral vector encoding shRNAs targeting TRIM34 or luciferase control (Luc) and the other shRNA vector specific for TRIM5α or Luc, for the knockdown as indicated. The pooled cells were challenged with VSV-G pseudotyped HIV-1 vectors expressing GFP reporter and containing CA-N74D (D), WT CA (E), or CA-P90A (F), across a range of viral inputs normalized for RT activity (RTU: Reverse Transcriptase Units/mL). The percentage of GFP-positive cells was determined 2 days later by flow cytometry. P values were determined using two-sided unpaired t-tests (ns = not significant, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).

To ask if this requirement of TRIM5α for TRIM34-mediated restriction is also important in primary cells, we knocked out either TRIM34 or TRIM5 in primary CD4+ cells and infected each cell pool with WT, N74D or P90A in comparison to a control cell pool (Fig 4C; TRIM34-KO 69% ICE KO-score, TRIM5-KO 87% ICE KO-score). Indeed, consistent with a requirement of TRIM5α for the TRIM34-medicated restriction, we find that knockout of either TRIM34 or TRIM5α is sufficient to rescue infection with the N74D capsid mutant (Fig 4C) while neither knockout has a significant effect on WT HIV-1 infection (Fig 4C).

We also examined this question in primary monocyte-derived dendritic cells (MoDCs) by transducing them with shRNA lentiviral vectors, resulting in stable knockdown of TRIM34 (TRIM34 KD) or TRIM5α (TRIM5 KD) (Fig 4D). In addition, to more directly ask if TRIM34 and TRIM5α work together or synergistically, we challenged cells in which both TRIM34 and TRIM5α were depleted simultaneously (TRIM5/TRIM34 DKD). Similar to our results in THP-1 and primary CD4+ T cells, infection with the HIV-1 N74D capsid mutant can be rescued by knockdown of either TRIM34 or TRIM5α in MoDCs (Fig 4D). In contrast, knockdown of either TRIM34 or TRIM5α does not have any effect on WT HIV-1 capsids (Fig 4E). Further, TRIM34 and TRIM5α act in the same pathway, rather than synergistically, to inhibit the HIV-1 N74D capsid mutant since a double-knockdown in MoDCs does not show any additional rescue (Fig 4D).

Finally, we asked if TRIM5α restriction of the CypA-binding deficient P90A capsid mutant virus depends on TRIM34. Consistent with the results of our initial screen with P90A (Fig 1B) and with other recently published results on TRIM5α-sensitivity of this virus [12], we find that P90A is more sensitive to TRIM5α restriction than HIV-1 WT (Fig 4C: CD4+ T Cells; Fig 4F: MoDCs). However, this restriction activity is independent of TRIM34 as TRIM34 knockout or knockdown has little to no effect on P90A (Fig 4C: CD4+ T Cells; Fig 4F: MoDCs). These data suggest that TRIM34 restriction depends on TRIM5α, but that TRIM5α restriction does not depend on TRIM34. Therefore, there is asymmetry in the TRIM5α/TRIM34 relationship as their interdependence is not equivalent across restriction activities.

TRIM34 and TRIM5α complexes colocalize with N74D capsids

Since TRIM34 restriction depends on TRIM5α (Fig 4), we tested the hypothesis that TRIM34 and TRIM5α colocalize with each other and with incoming HIV-1 capsids during infection. First, we created HeLa cell lines stably-expressing YFP-TRIM5α and HA-TRIM34 to ask if both proteins localize to the same subcellular compartment in cells. We find that TRIM34 localizes to cytoplasmic puncta, commonly referred to as cytoplasmic bodies, both together with and separate from TRIM5α (Fig 5A–“Mock”; white triangles are puncta with colocalization of TRIM34 and TRIM5α).

Fig 5 — HeLa cells were transduced to express YFP-TRIM5α (green) and HA-TRIM34 stably. They were plated on coverslips and synchronously infected with VSV-G pseudotyped HIV-1 with WT or N74D viruses as indicated. At 2 hpi, cells were fixed and stained for viral capsid protein p24^gag+ (blue) and HA-TRIM34 tag (red). Images from 15–20 cells were collected per condition in three independent biological replicates. A: Representative images for mock-infected cells (top row), WT-infected cells (middle row), and N74D-infected cells (bottom row). White triangles indicate colocalization of TRIM34 and TRIM5α in the zoomed in images for each channel. Triple colocalization between TRIM34, TRIM5α and p24^gag+ are indicated by arrowheads in the zoomed in images for each channel. B: Quantification of percent p24^gag+ colocalizing with both TRIM34 and TRIM5α for the WT and N74D virus. Error bars represent s.e.m. of all events collected across three biological replicates for each condition. P value was determined by a two-sided unpaired t-test.

Given that TRIM34, together with TRIM5α, restricts N74D capsids but not WT capsids, we hypothesized that this differential restriction could be due to the localization of TRIM34 and TRIM5α to N74D capsids that does not occur, or does not occur to the same extent, as with WT capsids. To test this hypothesis, HA-TRIM34 and YFP-TRIM5α stably-expressing HeLa cells were infected with WT or the N74D viruses and 2 hours later colocalization of both TRIM34 and TRIM5α with each capsid was measured. We observe colocalization of TRIM34 and TRIM5α together with both WT and N74D HIV-1 capsids in the cell cytoplasm (Fig 5A–WT and N74D; white arrowheads are puncta with p24^gag, TRIM34 and TRIM5α). Quantification of the number of p24^gag+ puncta that are also positive for TRIM34 and TRIM5α shows that colocalization of both TRIM proteins with p24^gag occurred more frequently for N74D capsids than for WT capsids (Fig 5B). Therefore, TRIM34 and TRIM5α are present together with incoming N74D HIV-1 capsids in the cytoplasm of infected cells.

Discussion

We identified TRIM34, a TRIM5 paralog, as an HIV-1 restriction factor capable of inhibiting infection by an HIV-1 N74D capsid mutant virus as well as several lentiviruses from monkeys. This block occurs before the completion of reverse transcription and is a constitutive block to infection as the restriction is observed in both IFN-stimulated and unstimulated cells. Moreover, TRIM34 restriction also occurs in primary, activated CD4+ T cells and monocyte-derived dendritic cells (MoDCs). The antiviral activity of TRIM34 is independent of the ability of viral capsids to bind CPSF6 but the antiviral restriction activity of TRIM34 requires TRIM5α in all cells tested. Finally, TRIM34 and TRIM5α colocalize in cells and preferentially localize to restricted N74D capsids as compared to WT capsids.

TRIM34 is a capsid-targeting HIV-1 restriction factor

While we did not identify here the factor responsible for enhanced sensitivity of the N74D mutant to IFN, we do uncover IFN-independent restriction by a novel capsid-targeting restriction factor, TRIM34. TRIM34 is a close paralog of the well-studied capsid-targeting restriction factor TRIM5. Previously, modest restriction of SIVmac and the non-primate lentivirus, Equine Infectious Anemia Virus (EIAV), by human TRIM34 was described but no effect of TRIM34 was observed on either WT HIV-1 or a G89V capsid mutant virus [9]. Our data suggest that TRIM34, together with TRIM5α, mediates all or most of the block to replication of the N74D capsid mutant observed in primary cells, including CD4+ T cells and MDMs, first described by Ambrose et al. [18]. The HIV-1 N74D capsid mutation is partially rescued by the capsid-binding inhibitor PF74 [35, 36], which suggests the possibility that PF74 might compete with TRIM34 restriction of this capsid. However, since the N74D mutation has pleiotropic effects, this rescue of the N74D mutant could also be independent of TRIM34.

TRIM5α knockout or knockdown rescues the HIV-1 P90A capsid mutant in human primary cells suggesting that at least one function of CypA binding is evasion of TRIM5α-mediated restriction [12]. Our screen with P90A did not uncover any additional factors, other than TRIM5α, suggesting that the increased IFN sensitivity of this mutant is entirely due to TRIM5α restriction.

TRIM34 as a species barrier

The site that sensitizes HIV-1 capsid to TRIM34 restriction, N74, is highly-conserved across HIV-1 and SIV strains [13]. Mutations at this site may sensitize capsids to TRIM34/TRIM5α restriction and therefore have been selected against. However, this effect is independent of CPSF6 binding to capsids as loss of binding to CPSF6 is not sufficient for restriction by TRIM34 (see the A77V mutant in Fig 3A and 3B and the N57A mutant in Fig 3C). Our results are consistent with the finding that WT capsids do not become IFN-hypersensitive in CPSF6 knockout cells [19]. Therefore, our data support a model in which CPSF6 binding plays a role in integration targeting [15–17, 37, 38] but it does not shield HIV-1 capsids from capsid-targeting restrictions. In contrast, loss of CypA binding sensitizes HIV-1 capsids to TRIM5α restriction [12]. However, loss of CypA binding is not sufficient for TRIM5α restriction of all primate lentiviruses as SIVmac is not restricted by TRIM5α even though SIVmac capsids do not bind CypA to any appreciable affinity [17]. These data together highlight the complexity of capsid adaptation to host restrictions where multiple, independent pathways of adaptation to multiple restrictions may occur across divergent strains.

The capsid-targeting restriction factors MxB and TRIM5α together with other restriction factors likely constrain HIV-1 evolution in vivo and provide a significant host barrier that HIV-1 must adapt to in order to successfully establish infection during transmission to a new host [39]. Capsid is a dominant determinant of species tropism for cross-species replication of primate lentiviruses such as SIVmac [40]. Our results suggest that TRIM34, like TRIM5α, is a lentiviral restriction factor that HIV-1 has adapted to in order to replicate efficiently in human cells since SIVs are also sensitive to human TRIM34. Further, TRIM34 may act more broadly across primates to restrict lentiviral infection, as rhesus macaque TRIM34 similarly blocks N74D replication (Fig 3G). Of note, rhesus macaque TRIM34 shows a similar pattern of restriction as human TRIM34 thereby suggesting that perhaps the specificity of TRIM34 restriction is determined by its interaction with TRIM5α. However, overexpression of TRIM5α alone is not sufficient to mediate restriction (Fig 3D and 3E). Taken together our results suggest that primate TRIM34, perhaps together with TRIM5α, could represent a significant barrier to cross-species transmission of primate lentiviruses. This interpretation is supported by the observation that N74 is a highly-conserved residue in lentiviral capsids.

TRIM34 restriction requires TRIM5α

Of particular interest, we find that TRIM34 restriction depends on TRIM5α. More broadly, TRIM proteins are a large gene family [41] and potentially-important functional interactions between family members likely have been overlooked. Our data show that TRIM34 can restrict lentiviral capsids but that this activity requires expression of TRIM5α, a close paralog of TRIM34. The ability of TRIM family members to hetero-oligomerize has been known for some time, but our screen highlights the power of an unbiased approach such as HIV-CRISPR screening to uncover previously-unappreciated functional interactions between TRIM family members.

This dependence of TRIM34 on TRIM5α raises several key questions including: 1) how does TRIM34 allow for specific restriction of the N74D capsid mutant viruses? and 2) why does this restriction depend on TRIM5α? We propose two potential models that are consistent with our data that are not mutually exclusive. First, it is possible that TRIM34 changes the specificity of TRIM5α such that it can now recognize the N74D capsid mutant virus better and/or more efficiently. TRIM34 can bind to HIV-1 capsids through its SPRY domain [29, 42]. However, when compared to TRIM5α, human TRIM34 has a deletion in the v1 loop of the SPRY domain that is important for determining capsid binding specificity. Further, TRIM34 is not itself evolving under positive selection, an evolutionary signature that would be consistent with a direct protein interface with a viral pathogen. Instead, it may be that the TRIM34 SPRY does not itself make significant contact with the N74D capsid but that TRIM34 complexing with TRIM5α may affect recognition of this capsid specifically by human TRIM5α.

A second possibility is that TRIM34 stabilizes TRIM5α, thereby allowing it to restrict N74D capsids. This model does not require any change in specificity of binding to capsid, per se, but rather results from changes in kinetics and/or entry of HIV-1 capsid mutants. Nuclear entry by HIV is highly dependent on cell type, including nuclear pore composition, and capsid sequence [22]. In this model, WT HIV-1 capsids are not sensitive to TRIM34 restriction as they transit the cytoplasm more efficiently and/or via a different nuclear entry route that allows escape from restriction. As proposed by Sultana et al., an accelerated rate of uncoating could be a mechanism of escape from cellular restrictions, particularly those that target the HIV-1 capsid [43]. In support of this model, it has been shown that while human TRIM5α has a short half-life and turns over quickly in cells, TRIM34 is significantly more stable [29]. It may be that TRIM34 stabilizes TRIM5α, thereby allowing it to restrict HIV capsids that transit differently than WT into the nucleus. In support of this model, slower uncoating kinetics of the N74D capsid mutant have been observed [44]. However, conflicting data shows that the N74D capsid mutant has been reported to have the same intrinsic stability as the WT capsid as measured by an in vitro uncoating assay [45].

A further implication of the interaction of TRIM34 and TRIM5α is that TRIM34 may play a role in sensing infection, the pattern recognition function of TRIM5α. The N74D capsid mutant has been proposed to trigger sensing pathways leading to IFN and other cytokine production in macrophages [20] although this phenotype of sensing of the N74D mutant occurs in macrophages has been challenged [33]. Work is currently underway to understand the potential role of TRIM34 in HIV sensing and pattern recognition/innate immune activation more broadly.

Materials and methods

Cells and cell culture

All cells were incubated in humidified, 5% CO₂ incubators at 37 °C. The THP-1 monocytic cell line (ATCC) was cultured in RPMI (Invitrogen) with 10% FBS, Pen/Strep, 10 mM HEPES, 0.11 g/L sodium pyruvate, 4.5 g/L D-Glucose and Glutamax. 293T (ATCC CRL-3216) and TZM-bl cells (ATCC 8129) were cultured in DMEM (Invitrogen) with 10% FBS and Pen/Strep. Puromycin selections in THP-1 cells were done at 0.5–1 ug/mL. The identity of THP-1 cells was confirmed by STR profiling (Fred Hutch Research Cell Bank). For the MoDC-related work, HEK293 cells (American Type Culture Collection) were cultured in DMEM supplemented with 10% heat-inactivated FBS, 20 mM GlutaMAX-I, 1 mM sodium pyruvate, 1× MEM non-essential amino acids and 25 mM HEPES, pH 7.2. HeLa and 293T cell lines utilized in the immunofluorescence assays were obtained from the American Type Culture Collection and were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals), 100 U/ml penicillin, 100 μg/ml streptomycin, and 10 μg/ml ciprofloxacin. To generate MoDCs, Peripheral Blood Mononuclear Cells (PBMCs) were isolated from leukopaks by gradient centrifugation on Lymphoprep (Axis-Shield Poc AS #AXS-1114546). CD14⁺ PBMCs were enriched using anti-CD14 antibody microbeads (Miltenyi Biotec #130-050-201), according to manufacturer’s protocol. The enriched CD14⁺ cells were cultured at a density of 2 × 10⁶ cells/mL, in RPMI-1640, supplemented with 5% heat-inactivated human AB⁺ serum (Omega Scientific), 20 mM GlutaMAX-I, 1 mM sodium pyruvate, 1× MEM non-essential amino acids and 25 mM HEPES pH 7.2. The addition of 1:100 cytokine-conditioned media containing hGM-CSF and hIL-4 to the culture promoted the differentiation of CD14+ cells into MoDCs. These cytokine-conditioned media were produced from HEK293 cells stably transduced with pAIP-hGMCSFco (Addgene no. 74168) or pAIP-hIL4-co (Addgene no. 74169), as previously described [46, 47]. For the analysis of reverse transcription products, a clonal TRIM34-KO THP-1 cell line was created through single-cell sorting of Cas9/RNP electroporated pools into 96-well plates to create individual clonal lines (BD FACS Aria II–Fred Hutch Flow Cytometry Core). A clonal KO line was identified through ICE Editing Analysis (Synthego). Universal Type I Interferon Alpha was obtained from PBL Assay Science (Catalog No. 11200–2), diluted to 10⁵ Units/mL in sterile-filtered PBS/1% BSA according to the activity reported by manufacturer and frozen in aliquots at −80°C.

Human blood

For CD4+ T cell experiments, whole blood from anonymous donors was obtained from BloodWorks Northwest, total PBMCs were isolated using the density gradient centrifugation method with Histopaque-1077 (Sigma-Aldrich #10771) and CD4+ T cells were isolated using EasySep Human CD4+ T cell isolation kit (StemCell Technologies #17952). Cells were resuspended to 2.5 x 10⁶ cells/mL in RPMI complete media supplemented with 10% FBS, Glutamax and Pen/Strep and with 100 U/mL recombinant human IL-2 (Roche; Sigma # 10799068001). For monocyte-derived dendritic cell (MoDC), leukopaks were acquired from anonymous, healthy blood donors (New York Biologics).

Ethics statement

All primary cell data is from anonymous blood donors and is classified as “human subjects exempt” research by the University of Massachusetts Medical School or Fred Hutchinson Cancer Research Center Institutional Review Boards, according to National Institutes of Health (NIH) guidelines (http://grants.nih.gov/grants/policy/hs/faqs_aps_definitions.htm). No animal work was done.

Plasmids

HIV infectious clones based on the LAI strain of HIV-1 (pLAI) were used in this study. The pLAI GFP3 backbone encodes the green fluorescent protein (GFP) gene in place of the nef gene [48]. The pLAI GFP3* WT, pLAI GFP3* N74D, pLAI GFP3* A77V and pLAI GFP3* N57A proviruses were provided by Masahiro Yamashita and are described in [33]. The P90A CA mutation was introduced into pLAI GFP3 using standard cloning procedures as described previously [49]. The luciferase envelope-defective reporter proviral N74D plasmid was cloned from pLAI GFP3* N74D by BssHI and SalI digest and cloned into BruLuc2deltaEnv [48]. The SIVmacLUC E-R- and SIVagmLUC E-R- plasmids were a gift from Ned Landau [50]. The lentiCRISPRv2 plasmid was a gift from Feng Zhang (Addgene #52961). pMD2.G and psPAX2 were gifts from Didier Trono (Addgene #12259/12260). lentiCRISPRv2 constructs targeting genes of interest were cloned into BsmBI-digested lentiCRISPRv2 by annealing complementary oligos with overhangs that allow directional cloning into lentiCRISPRv2. TRIM34 oligos used were: TRIM34KO_1: TRIM34_1 Sense CACCGGTCAAGTTGAGCCCAGACAA and TRIM34_1 Antisense AAACTTGTCTGGGCTCAACTTGACC; TRIM34KO_2: TRIM34_2 Sense CACCGGAGTAACTGATACCACACAC and TRIM34_2 Antisense AAACGTGTGTGGTATCAGTTACTCC). TRIM5 oligos used were: TRIM5KO: TRIM5 Sense CACCGGTTGATCATTGTGCACGCCA and TRIM5 Antisense AAACTGGCGTGCACAATGATCAACC). The lentiviral pHIV-dTomato (Addgene #21374) expression vector was a gift from Bryan Welm (Addgene plasmid #21374; http://n2t.net/addgene:21374; RRID:Addgene_21374). The human TRIM34 cDNA was purchased from Genscript (NM_001003827.1). Human TRIM34 was cloned into pHIV/dTomato using NotI and XmaI sites with an HA tag encoded at the N-terminus. The macaque TRIM34 cDNA (NM_001205182.3) was synthesized by Integrated DNA Technologies (IDT) and cloned into pHIV/dTomato using NotI and XmaI sites. For HeLa immunofluorescence assays, YFP- TRIM5α and HA-TRIM34 were cloned in frame, into retroviral vectors EXN and YXN as described previously [51].

Virus and lentivirus production

Replication-competent HIV-1 viruses were produced as previously described [6]. Briefly, 293T cells (ATCC) were plated at 2 × 10⁵ cells/mL in 2 mL in 6-well plates one day prior to transfection using TransIT-LT1 reagent (Mirus Bio LLC) with 3 μL of transfection reagent per μg of DNA. For HIV-1 production, 293Ts were transfected with 1 ug/well proviral DNA. One day post-transfection media was replaced. Two- or three- days post-transfection viral supernatants were clarified by centrifugation (1000 g) and filtered through a 20 μm filter. For Benzonase-treated viral preps, viral supernatants were incubated with 1 uL Benzonase (Sigma Aldrich #E1014) per 1mL of viral supernatant for 30 minutes at 37°C after dilution in 10X Benzonase Buffer (500mM Tris-HCl pH 8.0, 10mM MgCl₂, 1 mg/mL Bovine Serum Albumin). For HIV-1 vectors used in Fig 4D–4F, HEK293 cells were seeded at 75% confluency in 6-well plates. Transfections were performed with 6.25 μL TransIT LT1 transfection reagent (Mirus) in 250 μL Opti-MEM (Gibco) with 2.49 μg total plasmid DNA. 2.18 μg of env-defective HIV-1 provirus containing GFP reporter was cotransfected with 0.31 μg pMD2.G VSV G plasmid (Addgene #12259). Simian immunodeficiency virus (SIV)−VLPs containing Vpx were produced by the transfection of 2.18 μg pSIV−Δpsi/94env/ΔVif/ΔVpr (Addgene #132928) and 0.31 μg pMD2.G plasmid. 16 hours post-transfection, the culture media was changed to the media for MoDC culture. Viral supernatant was harvested 2 days later, filtered through a 0.45 μm filter and stored at −80 °C. For lentiviral preps (lentiCRISPRv2 and pHIV), 293Ts were transfected with 667 ng lentiviral plasmid, 500 ng psPAX2 and 333 ng MD2G. For PIKA_HIV library preps, supernatants from 20 × 6 well plates were combined and concentrated by ultracentrifugation. 30 mL of supernatant per SW-28 tube were underlaid with sterile-filtered 20% sucrose (1 mM EDTA, 20 mM HEPES, 100 mM NaCl, 20% sucrose) and spun in an SW28 rotor at 23,000 rpm for 1 hr at 4°C in a Beckman Coulter Optima L-90K Ultracentrifuge. Supernatants were decanted, pellets resuspended in DMEM over several hours at 4°C and aliquots frozen at −80°C. All viral and lentiviral infections and transductions, except those in Figs 4D–4F or 5, were done in the presence of 20 μg/mL DEAE-Dextran (Sigma #D9885).

HIV-CRISPR screening & screen analysis

HIV-CRISPR Screening and Analysis was performed as described [6] with the ISG-enriched PIKA_HIV library with the exception that the viral dose used in each screen allowed for infection of only ~10–30% of cells for each capsid mutant virus. All screens were performed in a clonal THP-1 ZAP-KO cell line [6]. Analysis of screen data was performed as previously described [6] with the exception that single mismatches were allowed when assigning reads to each sample during multiplexing. Sequencing data is available through the Gene Expression Omnibus (GEO–GSE140467).

Transduction with lentiviral knockdown, knockout and overexpression vectors

For stable overexpression of TRIM34, THP-1 cells were transduced with pHIV/dTomato-TRIM34 or pHIV/dTomato empty vector lentiviral preps. 2–5 days post-transduction cells were sorted for high dTomato expression to select for high-expressing populations. Transduced cells were resorted as needed. For shRNA knockdown in MoDCs, 2 × 10⁶ CD14⁺ monocytes/mL were transduced with a 1:4 volume of SIV−VLPs and a 1:4 volume of knockdown lentivectors, as indicated. The SIV−VLPs were added to transfer Vpx to the cells in order to overcome restriction by SAMHD1 against lentiviral transduction [52, 53]. Transduced cells were then selected with both 3 μg/mL puromycin (InvivoGen #ant-pr-1) and 10 μg/mL blasticidin (InvivoGen #ant-bl-1) for 3 days, starting at day 3 post-transduction. To generate stable HeLa cell lines used in immunofluorescence assays, a retrovirus was prepared by transfecting equal amounts of VSV-G, pCigB packaging plasmid, EXN HA-TRIM34 or YXN YFP-TRIM5 into HEK293T cells. Viral supernatant was harvested and filtered through 0.45 μm filters (Milipore) and applied to HeLa cells. 48 hrs after transduction, G418 was added to the cells, and following selection, cells were collected to check protein expression by Western blotting. To generate KO pools, THP-1 cells were transduced with lentiCRISPRv2 vectors and selection in Puromycin. KO cell pools were validated using genomic editing analysis as described below (Editing Analysis).

Cas9/RNP electroporation

Multiplexed Gene Knockout Kits targeting TRIM34 and TRIM5 were purchased from Synthego. The TRIM5 Kit includes the following sgRNA sequences: AAUCUUGCUUAACGUACAAG, UGGCCACAGUCUAGACUCAA and GAGGCAGUGACCAGCAUGGG. Primers used to amplify the genomic locus and sequencing for TRIM5 were: GAAAAGCCCTTATTACCAGG (For) and GAGAATCCATGACTTGGAAG (Rev). The TRIM34 Kit includes the following sgRNA target sequences: AGGUCUUGUGGUUUGCAGUG, AGGGGUUAAUGUAAAGGAGG and GGGAACUGAUCCGGCACACA. TRIM34 amplification and sequencing primers were provided with the kit. CD4+ T cells were activated for 3 days with 10 ug/mL of plate-bound anti-CD3 (Tonbo Biosciences, clone UCHT1; #70-0038-U100) and 5 ug/mL of diffused anti-CD28 (Tonbo Biosciences, clone CD28.2; #70-0289-U100). For each electroporation 1 x 10⁶ CD4+ T cells were pelleted by centrifugation at 100 x g for 10 mins and washed once in PBS. Cells were resuspended in 25 uL of CRISPR/Cas9 crRNP complexes that were pre-assembled in P3 Primary Cell Nucleofector Solution (Lonza #V4SP-3096) before electroporation in a single well of a 96-well Nucleocuvette Plate using program EH-115. Each electroporation was diluted with 80 uL of RPMI complete + 125 U/mL IL-2 and allowed to recover for 1–2 hours at 37°C. Cells resuspended at 2.5 x 10⁶ cells/mL were transferred to a 96-well plate in RPMI complete + 100 U/mL IL-2 and re-activated with anti-CD2/CD3/CD28 beads at a 1:1 ratio (T Cell Activation/Expansion Kit, Milltenyi Biotec #130-091-441). Two days post-electroporation, each well was supplemented with 100 uL of RPMI complete + 100 U/mL IL-2. Beginning from 4 days post-electroporation, cells were maintained and propagated at 1 x 10⁶ cells/mL with fresh RPMI complete + 100 U/mL IL-2 being added every 2–3 days until infection and editing analysis.

Editing analysis

Cell populations were analyzed for allele editing frequency as previously described [6]. Briefly, genomic DNA was isolated with a QIAamp DNA Mini Kit (Qiagen #51185), amplified by primers surrounding the editing site and sanger sequenced. Editing levels were analyzed by ICE Analysis (Synthego) to obtain an ICE KO-Score (ice.synthego.com/#/).

Exogenous reverse transcriptase assay

A 5 μL transfection supernatant containing virions was lysed in 5 μL 0.25% Triton X-100, 50 mM KCl, 100 mM Tris−HCl pH 7.4 and 0.4 U/μL RiboLock RNase inhibitor. This viral lysate was then diluted 1:100 in 5 mM (NH₄)₂SO₄, 20 mM KCl and 20 mM Tris−HCl pH 8.3. 10 μL of this was then added to a single step, RT−PCR assay with 35 nM bacteriophage MS2 RNA (Integrated DNA Technologies) as a template, 500 nM of each primer (5’-TCCTGCTCAACTTCCTGTCGAG-3’ and 5’-CACAGGTCAAACCTCCTAGGAATG-3’) and 0.1 μL hot-start Taq DNA polymerase (Promega) in 20 mM Tris−HCl pH 8.3, 5 mM (NH₄)₂SO₄, 20 mM KCl, 5 mM MgCl₂, 0.1 mg/mL BSA, 1/20,000 SYBR Green I (Invitrogen) and 200 μM dNTPs in a total reaction volume of 20 μL. The RT−PCR reaction was carried out in a Bio-Rad CFX96 cycler with the following parameters: 42 °C for 20 min, 95 °C for 2 min and 40 cycles (95 °C for 5 s, 60 °C for 5 s, 72 °C for 15 s and acquisition at 80 °C for 5 s).

Viral Infectivity assays

Cells were pre-stimulated with IFNα 24 hours prior to infection where indicated. Virus and 20 μg/mL DEAE-Dextran in RPMI were added to cells, spinoculated for 20 min at 1100xg, and incubated overnight at 37°C. Cells were washed the next day and re-suspended in RPMI supplemented with IFNα. For infectivity assays using single-cycle viruses in MoDCs, 2.5 × 10⁵ cells were plated per well, in a 48-well plate, on the day of virus challenge. Media containing VSV G-pseudotyped HIV-1 vectors encoding GFP reporter was added to challenge cells in a total volume of 250 μL per condition. Cells were harvested for flow cytometric analysis by scraping at 48 hours post-challenge with the HIV-1 vectors and fixed in a 1:4 dilution of BD Cytofix Fixation Buffer with phosphate-buffered saline (PBS) without Ca2⁺ and Mg2⁺, supplemented with 2% FBS and 0.1% NaN3.

Flow cytometry

For intracellular p24^gag staining, cells were harvested and fixed in 4% paraformaldehyde for 10 min and diluted to 1% in PBS. Cells were permeabilized in 0.5% Triton-X for 10 min and stained with 1:300 KC57-FITC (Beckman Coulter 6604665; RRID: AB_1575987). Data were collected on Accuri C6 (BD Biosciences–U Mass) or a BD FACSCANTO II (Fred Hutch Flow Cytometry Core) and analyzed with FlowJo software. For cell surface marker staining, cells were washed twice in PBS, stained in PBS/1% BSA, incubated at 4°C for 1 hr, washed twice in PBS, and analyzed on the Canto two flow cytometer (Fred Hutch Flow Cytometry Core).

Luciferase assay

For analysis of Luciferase activity, infected cells were lysed in 100 μL BrightGlo Luciferase reagent (Promega #E2610) and read on a LUMIstar Omega Luminometer.

qPCR assay for HIV late reverse transcription products

For qPCR analysis of HIV-1 late RT products, THP-1 cells were infected in 6-well plates with Benzonase-treated viral preparations (see Virus production methods). Total DNA was extracted from infected cells approx. 16 hours post-infection with a QIAprep Spin Miniprep kit (Qiagen #27106). HIV-1 cDNA was amplified using TaqMan Gene expression Master Mix (AppliedBiosystems #4369016) with 900nM of each primer: J1 FWD (Late RT F)–ACAAGCTAGTACCAGTTGAGCCAGATAAG, J2 REV (Late RT R)–GCCGTGCGCGCTTCAGCAAGC and 250nM LRT-P (late RT Probe)–FAM-CAGTGGCGCCCGAACAGGGA-TAMRA. qPCR data was collected on an ABI QuantStudio5 Real Time (qPCR) System Instrument.

Immunofluorescence microscopy

HeLa cells were allowed to adhere to glass coverslips placed in wells of a 24-well plate. Synchronized infection was performed by spinoculation of reporter virus onto cells at 13°C for 2 hours at 1,200 × g, after which virus-containing medium was removed and replaced with warm media. Coverslips containing cells were incubated in 37°C for 2 hours, and were subsequently fixed with 3.7% formaldehyde (Polysciences) in 0.1 M PIPES [piperazine-N,N’-bis(2-ethanesulfonic acid)], pH 6.8. Cells were permeabilized with 0.1% saponin, 10% normal donkey serum, 0.01% sodium azide in PBS. The following primary antibodies were used for immunofluorescence: mouse anti-HIV-1 p24^gag (Santa Cruz, Cat. # sc-69728), rabbit anti-HA (Sigma, Cat. # H6908). Primary antibodies were labeled with fluorophore-conjugated donkey anti-mouse or anti-rabbit antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Images were collected with a DeltaVision microscope (Applied Precision, Issaquah, WA, USA) equipped with a digital camera (CoolSNAP HQ; Photometrics, Tucson, AZ, USA), using a 1.4-numerical aperture (NA) 100x objective lens, and were deconvolved with SoftWoRx software (Applied Precision, Issaquah, WA, USA).

For each condition in each experiment, 15 Z-stack images were acquired using identical acquisition parameters. Deconvolved images were analyzed using Imaris Software (Bitplane). For analysis of colocalization between p24^gag and HA-TRIM34 and/or YFP- TRIM5α, an algorithm was designed to create a three-dimensional surface around p24^gag signal. The algorithm was applied to all the images within a given experiment. Colocalization was defined as the presence of a signal intensity above a threshold value, and the same colocalization threshold was maintained for a given channel for all the images and conditions in a particular experiment. Both graphing and statistics calculations were performed in Prism (Graphpad Software, Inc).

Supporting information

S1 Table. MAGeCK Gene Scores for all HIV-CRISPR screens.

WT +IFN (Tab 1), P90A +IFN (Tab 2), N74D +IFN (Tab 3), N74D noIFN (Tab 4). NegLog10PosGeneScore column shows -log₁₀MAGeCK Gene Scores.

(XLSX)

Click here for additional data file.^{(1.6MB, xlsx)}

Acknowledgments

We thank Masa Yamashita, ADARC, for providing capsid mutant proviral plasmids, including the unpublished HIV-1 P90A capsid mutant provirus, Daryl Humes for help with CD4 T cell preparations and electroporations, Sydney Fine for performing editing analysis on edited T cell pools and the Fred Hutch Genomics Core, including Jeff Delrow and Ryan Basom, for help with deep sequencing and HIV-CRISPR screen analysis. We are also grateful to the anonymous blood donors who contributed cells to this study.

Data Availability

All relevant data are within the manuscript, its Supporting Information files or available through the Gene Expression Omnibus (GEO - GSE140467).

Funding Statement

This work was supported by grants from National Institutes of Health (NIH): R01 AI147877 (M.O.), CFAR AI027757 (M.O.), P50 AI150464-13 (M.O.), R01 AI30927 (M.E), R37 AI147868 (J.L.) and R01 AI093258 (E.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1.Yamashita M, Engelman AN. Capsid-Dependent Host Factors in HIV-1 Infection. Trends Microbiol. 2017. Epub 2017/05/23. 10.1016/j.tim.2017.04.004 . [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Campbell EM, Hope TJ. HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol. 2015;13(8):471–83. Epub 2015/07/17. 10.1038/nrmicro3503 . [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Ambrose Z, Aiken C. HIV-1 uncoating: connection to nuclear entry and regulation by host proteins. Virology. 2014;454–455:371–9. Epub 2014/02/25. 10.1016/j.virol.2014.02.004 . [DOI] [PMC free article] [PubMed] [Google Scholar]
4.Hilditch L, Towers GJ. A model for cofactor use during HIV-1 reverse transcription and nuclear entry. Curr Opin Virol. 2014;4:32–6. Epub 2014/02/15. 10.1016/j.coviro.2013.11.003 . [DOI] [PMC free article] [PubMed] [Google Scholar]
5.Malim MH, Bieniasz PD. HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med. 2012;2(5):a006940 Epub 2012/05/04. 10.1101/cshperspect.a006940 . [DOI] [PMC free article] [PubMed] [Google Scholar]
6.OhAinle M, Helms L, Vermeire J, Roesch F, Humes D, Basom R, et al. A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife. 2018;7 Epub 2018/12/07. 10.7554/eLife.39823 . [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Jimenez-Guardeno JM, Apolonia L, Betancor G, Malim MH. Immunoproteasome activation enables human TRIM5alpha restriction of HIV-1. Nat Microbiol. 2019;4(6):933–40. Epub 2019/03/20. 10.1038/s41564-019-0402-0 . [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Ganser-Pornillos BK, Pornillos O. Restriction of HIV-1 and other retroviruses by TRIM5. Nat Rev Microbiol. 2019. Epub 2019/07/18. 10.1038/s41579-019-0225-2 . [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Zhang F, Hatziioannou T, Perez-Caballero D, Derse D, Bieniasz PD. Antiretroviral potential of human tripartite motif-5 and related proteins. Virology. 2006;353(2):396–409. Epub 2006/07/11. 10.1016/j.virol.2006.05.035 . [DOI] [PubMed] [Google Scholar]
10.Li X, Yeung DF, Fiegen AM, Sodroski J. Determinants of the higher order association of the restriction factor TRIM5alpha and other tripartite motif (TRIM) proteins. J Biol Chem. 2011;286(32):27959–70. Epub 2011/06/18. 10.1074/jbc.M111.260406 . [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell. 1993;73(6):1067–78. Epub 1993/06/18. 10.1016/0092-8674(93)90637-6 . [DOI] [PubMed] [Google Scholar]
12.Kim K, Dauphin A, Komurlu S, McCauley SM, Yurkovetskiy L, Carbone C, et al. Cyclophilin A protects HIV-1 from restriction by human TRIM5alpha. Nat Microbiol. 2019. Epub 2019/10/23. 10.1038/s41564-019-0592-5 . [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Lee K, Ambrose Z, Martin TD, Oztop I, Mulky A, Julias JG, et al. Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe. 2010;7(3):221–33. Epub 2010/03/17. 10.1016/j.chom.2010.02.007 . [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Price AJ, Fletcher AJ, Schaller T, Elliott T, Lee K, KewalRamani VN, et al. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog. 2012;8(8):e1002896 Epub 2012/09/08. 10.1371/journal.ppat.1002896 . [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Sowd GA, Serrao E, Wang H, Wang W, Fadel HJ, Poeschla EM, et al. A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin. Proc Natl Acad Sci U S A. 2016;113(8):E1054–63. Epub 2016/02/10. 10.1073/pnas.1524213113 . [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Rasheedi S, Shun MC, Serrao E, Sowd GA, Qian J, Hao C, et al. The Cleavage and Polyadenylation Specificity Factor 6 (CPSF6) Subunit of the Capsid-recruited Pre-messenger RNA Cleavage Factor I (CFIm) Complex Mediates HIV-1 Integration into Genes. J Biol Chem. [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Schaller T, Ocwieja KE, Rasaiyaah J, Price AJ, Brady TL, Roth SL, et al. HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog. 2011;7(12):e1002439 Epub 2011/12/17. 10.1371/journal.ppat.1002439 . [DOI] [PMC free article] [PubMed] [Google Scholar]
18.Ambrose Z, Lee K, Ndjomou J, Xu H, Oztop I, Matous J, et al. Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection. J Virol. 2012;86(8):4708–14. Epub 2012/02/04. 10.1128/JVI.05887-11 . [DOI] [PMC free article] [PubMed] [Google Scholar]
19.Bulli L, Apolonia L, Kutzner J, Pollpeter D, Goujon C, Herold N, et al. Complex Interplay between HIV-1 Capsid and MX2-Independent Alpha Interferon-Induced Antiviral Factors. J Virol. 2016;90(16):7469–80. 10.1128/JVI.00458-16 . [DOI] [PMC free article] [PubMed] [Google Scholar]
20.Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature. 2013;503(7476):402–5. Epub 2013/11/08. 10.1038/nature12769 . [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15(12):554 10.1186/s13059-014-0554-4 . [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Kane M, Rebensburg SV, Takata MA, Zang TM, Yamashita M, Kvaratskhelia M, et al. Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2. Elife. 2018;7 Epub 2018/08/08. 10.7554/eLife.35738 . [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Busnadiego I, Kane M, Rihn SJ, Preugschas HF, Hughes J, Blanco-Melo D, et al. Host and viral determinants of Mx2 antiretroviral activity. J Virol. 2014;88(14):7738–52. Epub 2014/04/25. 10.1128/JVI.00214-14 . [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Goujon C, Moncorge O, Bauby H, Doyle T, Ward CC, Schaller T, et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature. 2013;502(7472):559–62. Epub 2013/09/21. 10.1038/nature12542 . [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ, et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature. 2013;502(7472):563–6. Epub 2013/10/15. 10.1038/nature12653 . [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Liu Z, Pan Q, Ding S, Qian J, Xu F, Zhou J, et al. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe. 2013;14(4):398–410. Epub 2013/09/24. 10.1016/j.chom.2013.08.015 . [DOI] [PubMed] [Google Scholar]
27.Liu Z, Pan Q, Liang Z, Qiao W, Cen S, Liang C. The highly polymorphic cyclophilin A-binding loop in HIV-1 capsid modulates viral resistance to MxB. Retrovirology. 2015;12:1 Epub 2015/01/13. 10.1186/s12977-014-0129-1 . [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Orimo A, Tominaga N, Yoshimura K, Yamauchi Y, Nomura M, Sato M, et al. Molecular cloning of ring finger protein 21 (RNF21)/interferon-responsive finger protein (ifp1), which possesses two RING-B box-coiled coil domains in tandem. Genomics. 2000;69(1):143–9. Epub 2000/10/03. 10.1006/geno.2000.6318 [DOI] [PubMed] [Google Scholar]
29.Li X, Gold B, O’HUigin C, Diaz-Griffero F, Song B, Si Z, et al. Unique features of TRIM5alpha among closely related human TRIM family members. Virology. 2007;360(2):419–33. Epub 2006/12/13. 10.1016/j.virol.2006.10.035 . [DOI] [PubMed] [Google Scholar]
30.Sawyer SL, Emerman M, Malik HS. Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals. PLoS Pathog. 2007;3(12):e197 Epub 2007/12/28. 10.1371/journal.ppat.0030197 . [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Sawyer SL, Wu LI, Emerman M, Malik HS. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci U S A. 2005;102(8):2832–7. Epub 2005/02/04. 10.1073/pnas.0409853102 . [DOI] [PMC free article] [PubMed] [Google Scholar]
32.De Iaco A, Luban J. Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus. Retrovirology. 2011;8:98 Epub 2011/12/08. 10.1186/1742-4690-8-98 . [DOI] [PMC free article] [PubMed] [Google Scholar]
33.Saito A, Henning MS, Serrao E, Dubose BN, Teng S, Huang J, et al. Capsid-CPSF6 Interaction Is Dispensable for HIV-1 Replication in Primary Cells but Is Selected during Virus Passage In Vivo. J Virol. 2016;90(15):6918–35. Epub 2016/06/17. 10.1128/JVI.00019-16 . [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Duggal NK, Emerman M. Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol. 2012;12(10):687–95. Epub 2012/09/15. 10.1038/nri3295 . [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Zhou J, Price AJ, Halambage UD, James LC, Aiken C. HIV-1 Resistance to the Capsid-Targeting Inhibitor PF74 Results in Altered Dependence on Host Factors Required for Virus Nuclear Entry. J Virol. 2015;89(17):9068–79. Epub 2015/06/26. 10.1128/JVI.00340-15 . [DOI] [PMC free article] [PubMed] [Google Scholar]
36.Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, et al. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 2010;6(12):e1001220 Epub 2010/12/21. 10.1371/journal.ppat.1001220 . [DOI] [PMC free article] [PubMed] [Google Scholar]
37.Bejarano DA, Peng K, Laketa V, Borner K, Jost KL, Lucic B, et al. HIV-1 nuclear import in macrophages is regulated by CPSF6-capsid interactions at the nuclear pore complex. Elife. 2019;8 Epub 2019/01/24. 10.7554/eLife.41800 . [DOI] [PMC free article] [PubMed] [Google Scholar]
38.Achuthan V, Perreira JM, Sowd GA, Puray-Chavez M, McDougall WM, Paulucci-Holthauzen A, et al. Capsid-CPSF6 Interaction Licenses Nuclear HIV-1 Trafficking to Sites of Viral DNA Integration. Cell Host Microbe. 2018;24(3):392–404 e8. Epub 2018/09/04. 10.1016/j.chom.2018.08.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis. 2010;201(11):1686–96. Epub 2010/04/28. 10.1086/652420 . [DOI] [PMC free article] [PubMed] [Google Scholar]
40.Hatziioannou T, Princiotta M, Piatak M Jr., Yuan F, Zhang F, Lifson JD, et al. Generation of simian-tropic HIV-1 by restriction factor evasion. Science. 2006;314(5796):95 Epub 2006/10/07. 10.1126/science.1130994 . [DOI] [PubMed] [Google Scholar]
41.Nisole S, Stoye JP, Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol. 2005;3(10):799–808. Epub 2005/09/22. 10.1038/nrmicro1248 . [DOI] [PubMed] [Google Scholar]
42.Yang Y, Brandariz-Nunez A, Fricke T, Ivanov DN, Sarnak Z, Diaz-Griffero F. Binding of the rhesus TRIM5alpha PRYSPRY domain to capsid is necessary but not sufficient for HIV-1 restriction. Virology. 2014;448:217–28. Epub 2013/12/10. 10.1016/j.virol.2013.10.012 . [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Sultana T, Mamede JI, Saito A, Ode H, Nohata K, Cohen R, et al. Multiple pathways to avoid IFN-beta sensitivity of HIV-1 by mutations in capsid. J Virol. 2019. Epub 2019/09/13. 10.1128/JVI.00986-19 . [DOI] [PMC free article] [PubMed] [Google Scholar]
44.Hulme AE, Kelley Z, Okocha EA, Hope TJ. Identification of capsid mutations that alter the rate of HIV-1 uncoating in infected cells. J Virol. 2015;89(1):643–51. Epub 2014/10/24. 10.1128/JVI.03043-14 . [DOI] [PMC free article] [PubMed] [Google Scholar]
45.Shah VB, Shi J, Hout DR, Oztop I, Krishnan L, Ahn J, et al. The host proteins transportin SR2/TNPO3 and cyclophilin A exert opposing effects on HIV-1 uncoating. J Virol. 2013;87(1):422–32. Epub 2012/10/26. 10.1128/JVI.07177-11 . [DOI] [PMC free article] [PubMed] [Google Scholar]
46.McCauley SM, Kim K, Nowosielska A, Dauphin A, Yurkovetskiy L, Diehl WE, et al. Intron-containing RNA from the HIV-1 provirus activates type I interferon and inflammatory cytokines. Nat Commun. 2018;9(1):5305 Epub 2018/12/14. 10.1038/s41467-018-07753-2 . [DOI] [PMC free article] [PubMed] [Google Scholar]
47.Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, Lascano J, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature. 2011;472(7343):361–5. Epub 2011/04/23. 10.1038/nature09976 . [DOI] [PMC free article] [PubMed] [Google Scholar]
48.Yamashita M, Emerman M. Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J Virol. 2004;78(11):5670–8. Epub 2004/05/14. 10.1128/JVI.78.11.5670-5678.2004 . [DOI] [PMC free article] [PubMed] [Google Scholar]
49.Henning MS, Dubose BN, Burse MJ, Aiken C, Yamashita M. In vivo functions of CPSF6 for HIV-1 as revealed by HIV-1 capsid evolution in HLA-B27-positive subjects. PLoS Pathog. 2014;10(1):e1003868 Epub 2014/01/15. 10.1371/journal.ppat.1003868 . [DOI] [PMC free article] [PubMed] [Google Scholar]
50.Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 2003;114(1):21–31. Epub 2003/07/16. 10.1016/s0092-8674(03)00515-4 . [DOI] [PubMed] [Google Scholar]
51.Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5(5):512–7. Epub 1999/05/06. 10.1038/8394 . [DOI] [PubMed] [Google Scholar]
52.Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011;474(7353):658–61. Epub 2011/07/02. 10.1038/nature10195 . [DOI] [PMC free article] [PubMed] [Google Scholar]
53.Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474(7353):654–7. Epub 2011/05/27. 10.1038/nature10117 . [DOI] [PMC free article] [PubMed] [Google Scholar]

PLoS Pathog. doi: 10.1371/journal.ppat.1008507.r001

Decision Letter 0

Susan R Ross, David T Evans

14 Jan 2020

Dear Dr. Ohainle,

Thank you very much for submitting your manuscript "TRIM34 acts with TRIM5α to restrict HIV-1 and SIV capsids" (PPATHOGENS-D-19-02127) for review by PLOS Pathogens. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the manuscript as it currently stands. These issues must be addressed before we would be willing to consider a revised version of your study. We cannot, of course, promise publication at that time.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

In addition, when you are ready to resubmit, please be prepared to provide the following:

(1) A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

(2) Two versions of the manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Additionally, to enhance the reproducibility of your results, PLOS recommends that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see http://journals.plos.org/plospathogens/s/submission-guidelines#loc-materials-and-methods

We hope to receive your revised manuscript within 60 days. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by replying to this email. Revised manuscripts received beyond 60 days may require evaluation and peer review similar to that applied to newly submitted manuscripts.

There is additional documentation related to this decision letter. To access the file(s), please click the link below. You may also login to the system and click the 'View Attachments' link in the Action column.

[LINK]

We are sorry that we cannot be more positive about your manuscript at this stage, but if you have any concerns or questions, please do not hesitate to contact us.

Sincerely,

David T. Evans

Associate Editor

PLOS Pathogens

Susan Ross

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Dear Molly,

I am sorry this has taken so long. The reviewers did the best they could, but were delayed both by the holiday season and the January 7th NIH AIDS review deadline. While the comments are generally positive, they have made some constructive suggestions that should be addressed to strengthen this work.

David

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: The manuscript describes results from a follow up study using the HIV-CRISPR screen to identify restriction factors targeting the N74D and P90A mutants of HIV-1 CA. TRIM34 was found to inhibit the N74D mutant, in a step that is prior to reverse transcription and in a process that is independent of CPSF6 binding but dependent on the presence of TRIM5α. The effect seems to be more pronounced in primary CD4+ T cells and TRIM34 also blocks SIVmac and SIVagm. The manuscript is well written and the findings provide important evidence for yet another capsid-dependent retrovirus restriction factor.

Reviewer #2: Ohainle et al. present interesting findings that provide some mechanistic insight into how TRIM34 inhibits HIV replication. While TRIM34 has previously been studyied in the context of lentiviruses, the authors show here that TRIM34 function requires TRIM5. Importantly, the authors take advantage of their HIV-CRISPR screening tool to generate these novel results in an unbiased manner. Overall, I feel that this manuscript is appropriate for PLOS Pathogens granted that some revisions are done.

Reviewer #3: In this manuscript, Ohainle et al. describe a novel interaction between human TRIM34 and HIV-1 capsid with the N74D mutation. They show that N74D HIV-1 and 2 SIV strains (but not WT HIV-1) are restricted by TRIM34 in both THP-1 cells and primary CD4+ T cells and monocyte-derived macrophages with or without type I IFN treatment. Restriction of N74D HIV-1 occurs at or before reverse transcription and requires the host restriction factor TRIM5a. In cells overexpressing tagged forms of TRIM5a and TRIM34, they can be colocalized with each other and are associated with capsid after infection with N74D HIV-1 but not WT HIV-1. Overall, the manuscript suggests that TRIM34 recognizes N74D CA (and SIV CA) in primary cells, leading to its previously described restriction. This finding could explain why N74 is highly conserved in primate lentiviruses.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: (No Response)

Reviewer #2: Major issues:

1. The authors should check to see how P90 affects restriction by TRIM34 in their ectopic TRIM34 expression system (Figure 2D).

2. Authors should perform the experiments in Figures 4A and 4B in the presence and absence of IFN (maybe they already have this?)

3. One noticeable absence from this paper is the study of non-human primate TRIM34. The authors indicate that TRIM34 is not rapidly-evolving in primates, but have they checked for overlapping function with human TRIM34? The authors have an experimental system in place to study ectopic TRIM34, so this would be an easy experiment to include. This would be a good addition to the paper because previous studies have already highlighted a role for TRIM34 in HIV restriction.

Reviewer #3: 1. The authors state that loss of CPSF6 binding is not sufficient for TRIM34 restriction as A77V HIV-1 is not restricted. However, this is an unusual mutant that is not restricted in general in macrophages. It would more convincing for the authors to evaluate other capsid mutants that do not bind to CPSF6 and are restricted in primary cells (i.e. N57A/S and/or A105T). Also, does TRIM34 restrict non-primate lentiviruses (i.e. FIV and EIAV)?

2. The authors initially identified TRIM34 restriction of N74D HIV-1 in IFN-treated THP-1 cells and state in Lines 322-325: "Our HIV-CRISPR screen demonstrates that the increased IFN-sensitivity of the HIV-1 N74D CA mutant [19] is not due to an increased sensitivity to the known capsid-targeting restriction factors TRIM5α or MxB (Figure 1B) but rather is due to restriction by a novel capsid-targeting restriction factor, TRIM34." However, other than this initial screen described in Figure 1 and data shown in Figure 2A, the remainder of the manuscript does not appear to include IFN-treated cells. In Figure 2, the level of restriction with or without IFN treatment is similar (2.2-fold vs. 2.0-fold, respectively). It is unclear how TRIM34 enhances IFN sensitivity, as this is not shown in the presented data.

3. CypA is discussed throughout the manuscript as being an important capsid-binding factor. Yet other than evaluation of P90A HIV-1 (and SIV), CypA is not directly addressed. This is surprising as 1) some of the co-authors of this manuscript recently published that CypA protects HIV-1 from TRIM5α and 2) Ambrose et al. showed that N74D HIV-1 is more sensitive to loss of CypA binding than WT HIV-1. Is TRIM34 restriction of N74D HIV-1 influenced by CypA?

4. There are some concerns regarding the imaging experiments in Figure 5. First, the data represent staining at 2h post-infection, which would be significantly later than capsid uncoating. Do the authors anticipate earlier binding of TRIM34/TRIM5α to N74D CA? Second, do the HeLa cells that express tagged TRIM34 and TRIM5α restrict N74D HIV-1? Finally, colocalization of N74D CA is higher with TRIM34 with half of them not associated with TRIM5α. Does this suggest a sequential interaction of the 2 host proteins with N74D capsid?

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: The TRIM34 restriction is only seen in lab generated mutants of HIV-1 capsid and not wild type. Unless these mutations occur naturally, the title claiming that TRIM34 restricts HIV-1 is a little misleading. Perhaps “primate lentiviral capsids” will be more appropriate.

Given that the restriction is stronger against the SIVs, it would seem that TRIM34 could work with TRIM5α to prevent cross-species transmission of primate lentiviruses, making the SIV results as important, if not more, than the weak effects seen with the artificial HIV-1 mutants. The authors have hinted at this in the penultimate paragraph on page 11 but the point could be emphasised more strongly.

TRIM34 scored as highly as the IFN pathway genes in the HIV-CRISPR screen. Yet, its effects are weak in subsequent experiments. Given that the readout of the HIV-CRISPR screen is from viruses that are released from infected cells, this would identify processes from early as well as late stages of the life cycle. However, the subsequent experiments measured percentage of infected cells after 48 hours, which is probably the result of a single cycle of infection, hence only early stages of the life cycle. If TRIM34 works with TRIM5α, which has been shown to also act as an immune sensor, the possibility that it could trigger the innate immune pathways cannot be discounted. This could activate genes that might act on the late stages of the viral life cycle and would not be picked up looking at infected cells from a single cycle infection. Indeed, N74D has been previously reported to trigger innate sensors due to lack of Cpsf6 binding. However, this will have to be reinterpreted in the light of the data from Fig 3A and 3B.

Other points:

Typos: Line 45 on page 2, “… the HIV-1 capsid protein is exposed to an array of …”

Line 150 on page 5, “However, unlike T TRIM5α ,…” T shouldn’t be there.

Fig 2A and 2B. The legend describes the assay as intracellular P24gag+ staining but the y-axis is labelled as %GFP+ cells. Is the readout p24gag+ or GFP+?

Fig 2C and Fig 3B. These are very similar experiments involving CD4+ T cells. However, the infectivities of WT and N74D viruses are different (5% GFP+ for WT, 1% GFP+ for N74D/TRIM34KO in Fig 2C; 1% GFP+ for WT, 4%GFP+ for N74D/TRIM34 KO in Fig3B). The effect of TRIM34KO also varies. (8x in Fig 2C and 4.2x in Fig 3B). Is it amount of input virus the same or normalized in anyway? The variation of 2-fold is of concern since some of the TRIM34 effects described (eg Fig 2A and 2B) are 2-fold.

Fig 2E. The significance of the graphs showing Neviparin treatments were not described in the text.

Reviewer #2: Minor issues:

1. Author summary: viruses don’t adapt to host genes, but rather host proteins. And HIV-1 does not interact with human genes (at least not in the sense that the authors are trying to describe). HIV-1 interacts with gene products (proteins).

2. Line 119: remove “are enriched in the viral supernatant.”

3. Fonts used to label different parts of Figure panels, including the titles, should be identical (I suggest Arial). For example, in Figure 2, “control” and “TRIM34” are Calibri, or something like that. This appears to be a common problem throughout all figures.

4. Figure 2: raw data (%GFP+ cells) makes an appearance in Figure 2. I suggest that some raw data is added to Figure 1 such that the effect of STAT, IFNAR, IRF9, and TRIM34 KO can be seen. It would also be nice to see the extent to which IFN inhibits LAI infection in THP1 here.

5. Can the authors discuss why TRIM34 KO rescues WT and N74D virus to nearly similar extents in the absence of IFN?

6. Line 187: what do the authors mean by a “knockout allele?”

7. Line 230: this statement is confusing. Actually, due to ongoing genetic conflicts between host and pathogens, restriction factors from one species may not restrict viruses adapted to other species (because virus capsids co-evolve with host-specific capsid-targeting factors). I suggest removing this line entirely as it is not required to ask whether TRIM34 acts broadly.

8. It is interesting to show and discuss the data in Figure 1 featuring both P90A and N74D. And the results from that Figure 1 justify a focus on N74D in subsequent figures. However, I would remove mention of P90A from the abstract as it is not the main focus of the paper and a recent paper has characterized the relationship between TRIM5 and this CypA binding deficient mutant.

9. I think that more discussion is warranted on the following topic: does TRIM5 need TRIM34 in order to restrict HIV (WT or N74D)? Why or why not? The authors only focus the discussion on how TRIM34 needs TRIM5alpha in order to restrict N74D. The title states how “TRIM34 works with TRIM5.” This word choice is vague, and it begs the question of whether some or all activities of TRIM5 are dependent on TRIM34. This title may also give the impression that TRIM34 and TRIM5 work in an additive (independent) fashion. An alternative title could be: “TRIM34 restricts HIV and SIV capsids in a TRIM5-dependent manner.”

10. The authors should include a mention of the data that TRIM34 has different specificity than TRIM5 (it inhibits SIVmac) in the Discussion. Can they speculate as to why TRIM34+TRIM5 may restrict SIVmac CA but TRIM5 alone does not?

11. Line 386: the language used here is confusing. Do references 43 and 44 conflict with one another? Does N74D exhibit slower uncoating kinetics in one paper but not the other? Similarly, at line 394, is it implied that N74D uncoats and transits more slowly than WT? Please clarify.

Reviewer #3: 1. Line 45: the word "an" should precede "array of capsid-targeting"

2. Lines 103-104: P90A is not CypA-deficient but rather CypA binding-deficient. Similarly, N74D is not CPSF6-deficient but deficient in binding to CPSF6.

3. Line 133: The preceding sentence describes "ISGs, including MXB (MX2), IFITM1, TETHERIN (BST2) and TRIM5." Only IFITM1 and TETHERIN is in cyan in Figure 1; TRIM5 and MXB are yellow and dark blue, respectively.

4. Line 327: should be "G89V" instead of "G98V"

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Alex Compton

Reviewer #3: No

Attachment

Submitted filename: Ohainle et al 2019 PLOS Pathogens.docx

Click here for additional data file.^{(16.1KB, docx)}

PLoS Pathog. 2020 Apr 13;16(4):e1008507. doi: 10.1371/journal.ppat.1008507.r002

Author response to Decision Letter 0

23 Mar 2020

Attachment

Submitted filename: 2020_03_23 Ohainle response to reviewers.docx

Click here for additional data file.^{(312.1KB, docx)}

PLoS Pathog. doi: 10.1371/journal.ppat.1008507.r003

Decision Letter 1

Susan R Ross, David T Evans

29 Mar 2020

Dear Dr. Ohainle,

We are pleased to inform you that your manuscript 'TRIM34 restricts HIV-1 and SIV capsids in a TRIM5α-dependent manner' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

David T. Evans

Associate Editor

PLOS Pathogens

Susan Ross

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

Reviewer Comments (if any, and for reference):

PLoS Pathog. doi: 10.1371/journal.ppat.1008507.r004

Acceptance letter

Susan R Ross, David T Evans

6 Apr 2020

Dear Dr. Ohainle,

We are delighted to inform you that your manuscript, "TRIM34 restricts HIV-1 and SIV capsids in a TRIM5α-dependent manner," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Table. MAGeCK Gene Scores for all HIV-CRISPR screens.

WT +IFN (Tab 1), P90A +IFN (Tab 2), N74D +IFN (Tab 3), N74D noIFN (Tab 4). NegLog10PosGeneScore column shows -log₁₀MAGeCK Gene Scores.

(XLSX)

Click here for additional data file.^{(1.6MB, xlsx)}

Attachment

Submitted filename: Ohainle et al 2019 PLOS Pathogens.docx

Click here for additional data file.^{(16.1KB, docx)}

Attachment

Submitted filename: 2020_03_23 Ohainle response to reviewers.docx

Click here for additional data file.^{(312.1KB, docx)}

Data Availability Statement

All relevant data are within the manuscript, its Supporting Information files or available through the Gene Expression Omnibus (GEO - GSE140467).

[ppat.1008507.ref001] 1.Yamashita M, Engelman AN. Capsid-Dependent Host Factors in HIV-1 Infection. Trends Microbiol. 2017. Epub 2017/05/23. 10.1016/j.tim.2017.04.004 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref002] 2.Campbell EM, Hope TJ. HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol. 2015;13(8):471–83. Epub 2015/07/17. 10.1038/nrmicro3503 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref003] 3.Ambrose Z, Aiken C. HIV-1 uncoating: connection to nuclear entry and regulation by host proteins. Virology. 2014;454–455:371–9. Epub 2014/02/25. 10.1016/j.virol.2014.02.004 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref004] 4.Hilditch L, Towers GJ. A model for cofactor use during HIV-1 reverse transcription and nuclear entry. Curr Opin Virol. 2014;4:32–6. Epub 2014/02/15. 10.1016/j.coviro.2013.11.003 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref005] 5.Malim MH, Bieniasz PD. HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med. 2012;2(5):a006940 Epub 2012/05/04. 10.1101/cshperspect.a006940 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref006] 6.OhAinle M, Helms L, Vermeire J, Roesch F, Humes D, Basom R, et al. A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife. 2018;7 Epub 2018/12/07. 10.7554/eLife.39823 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref007] 7.Jimenez-Guardeno JM, Apolonia L, Betancor G, Malim MH. Immunoproteasome activation enables human TRIM5alpha restriction of HIV-1. Nat Microbiol. 2019;4(6):933–40. Epub 2019/03/20. 10.1038/s41564-019-0402-0 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref008] 8.Ganser-Pornillos BK, Pornillos O. Restriction of HIV-1 and other retroviruses by TRIM5. Nat Rev Microbiol. 2019. Epub 2019/07/18. 10.1038/s41579-019-0225-2 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref009] 9.Zhang F, Hatziioannou T, Perez-Caballero D, Derse D, Bieniasz PD. Antiretroviral potential of human tripartite motif-5 and related proteins. Virology. 2006;353(2):396–409. Epub 2006/07/11. 10.1016/j.virol.2006.05.035 . [DOI] [PubMed] [Google Scholar]

[ppat.1008507.ref010] 10.Li X, Yeung DF, Fiegen AM, Sodroski J. Determinants of the higher order association of the restriction factor TRIM5alpha and other tripartite motif (TRIM) proteins. J Biol Chem. 2011;286(32):27959–70. Epub 2011/06/18. 10.1074/jbc.M111.260406 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref011] 11.Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell. 1993;73(6):1067–78. Epub 1993/06/18. 10.1016/0092-8674(93)90637-6 . [DOI] [PubMed] [Google Scholar]

[ppat.1008507.ref012] 12.Kim K, Dauphin A, Komurlu S, McCauley SM, Yurkovetskiy L, Carbone C, et al. Cyclophilin A protects HIV-1 from restriction by human TRIM5alpha. Nat Microbiol. 2019. Epub 2019/10/23. 10.1038/s41564-019-0592-5 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref013] 13.Lee K, Ambrose Z, Martin TD, Oztop I, Mulky A, Julias JG, et al. Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe. 2010;7(3):221–33. Epub 2010/03/17. 10.1016/j.chom.2010.02.007 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref014] 14.Price AJ, Fletcher AJ, Schaller T, Elliott T, Lee K, KewalRamani VN, et al. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog. 2012;8(8):e1002896 Epub 2012/09/08. 10.1371/journal.ppat.1002896 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref015] 15.Sowd GA, Serrao E, Wang H, Wang W, Fadel HJ, Poeschla EM, et al. A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin. Proc Natl Acad Sci U S A. 2016;113(8):E1054–63. Epub 2016/02/10. 10.1073/pnas.1524213113 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref016] 16.Rasheedi S, Shun MC, Serrao E, Sowd GA, Qian J, Hao C, et al. The Cleavage and Polyadenylation Specificity Factor 6 (CPSF6) Subunit of the Capsid-recruited Pre-messenger RNA Cleavage Factor I (CFIm) Complex Mediates HIV-1 Integration into Genes. J Biol Chem. [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref017] 17.Schaller T, Ocwieja KE, Rasaiyaah J, Price AJ, Brady TL, Roth SL, et al. HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog. 2011;7(12):e1002439 Epub 2011/12/17. 10.1371/journal.ppat.1002439 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref018] 18.Ambrose Z, Lee K, Ndjomou J, Xu H, Oztop I, Matous J, et al. Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection. J Virol. 2012;86(8):4708–14. Epub 2012/02/04. 10.1128/JVI.05887-11 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref019] 19.Bulli L, Apolonia L, Kutzner J, Pollpeter D, Goujon C, Herold N, et al. Complex Interplay between HIV-1 Capsid and MX2-Independent Alpha Interferon-Induced Antiviral Factors. J Virol. 2016;90(16):7469–80. 10.1128/JVI.00458-16 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref020] 20.Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature. 2013;503(7476):402–5. Epub 2013/11/08. 10.1038/nature12769 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref021] 21.Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15(12):554 10.1186/s13059-014-0554-4 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref022] 22.Kane M, Rebensburg SV, Takata MA, Zang TM, Yamashita M, Kvaratskhelia M, et al. Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2. Elife. 2018;7 Epub 2018/08/08. 10.7554/eLife.35738 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref023] 23.Busnadiego I, Kane M, Rihn SJ, Preugschas HF, Hughes J, Blanco-Melo D, et al. Host and viral determinants of Mx2 antiretroviral activity. J Virol. 2014;88(14):7738–52. Epub 2014/04/25. 10.1128/JVI.00214-14 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref024] 24.Goujon C, Moncorge O, Bauby H, Doyle T, Ward CC, Schaller T, et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature. 2013;502(7472):559–62. Epub 2013/09/21. 10.1038/nature12542 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref025] 25.Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ, et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature. 2013;502(7472):563–6. Epub 2013/10/15. 10.1038/nature12653 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref026] 26.Liu Z, Pan Q, Ding S, Qian J, Xu F, Zhou J, et al. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe. 2013;14(4):398–410. Epub 2013/09/24. 10.1016/j.chom.2013.08.015 . [DOI] [PubMed] [Google Scholar]

[ppat.1008507.ref027] 27.Liu Z, Pan Q, Liang Z, Qiao W, Cen S, Liang C. The highly polymorphic cyclophilin A-binding loop in HIV-1 capsid modulates viral resistance to MxB. Retrovirology. 2015;12:1 Epub 2015/01/13. 10.1186/s12977-014-0129-1 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref028] 28.Orimo A, Tominaga N, Yoshimura K, Yamauchi Y, Nomura M, Sato M, et al. Molecular cloning of ring finger protein 21 (RNF21)/interferon-responsive finger protein (ifp1), which possesses two RING-B box-coiled coil domains in tandem. Genomics. 2000;69(1):143–9. Epub 2000/10/03. 10.1006/geno.2000.6318 [DOI] [PubMed] [Google Scholar]

[ppat.1008507.ref029] 29.Li X, Gold B, O’HUigin C, Diaz-Griffero F, Song B, Si Z, et al. Unique features of TRIM5alpha among closely related human TRIM family members. Virology. 2007;360(2):419–33. Epub 2006/12/13. 10.1016/j.virol.2006.10.035 . [DOI] [PubMed] [Google Scholar]

[ppat.1008507.ref030] 30.Sawyer SL, Emerman M, Malik HS. Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals. PLoS Pathog. 2007;3(12):e197 Epub 2007/12/28. 10.1371/journal.ppat.0030197 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref031] 31.Sawyer SL, Wu LI, Emerman M, Malik HS. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci U S A. 2005;102(8):2832–7. Epub 2005/02/04. 10.1073/pnas.0409853102 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref032] 32.De Iaco A, Luban J. Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus. Retrovirology. 2011;8:98 Epub 2011/12/08. 10.1186/1742-4690-8-98 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref033] 33.Saito A, Henning MS, Serrao E, Dubose BN, Teng S, Huang J, et al. Capsid-CPSF6 Interaction Is Dispensable for HIV-1 Replication in Primary Cells but Is Selected during Virus Passage In Vivo. J Virol. 2016;90(15):6918–35. Epub 2016/06/17. 10.1128/JVI.00019-16 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref034] 34.Duggal NK, Emerman M. Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol. 2012;12(10):687–95. Epub 2012/09/15. 10.1038/nri3295 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref035] 35.Zhou J, Price AJ, Halambage UD, James LC, Aiken C. HIV-1 Resistance to the Capsid-Targeting Inhibitor PF74 Results in Altered Dependence on Host Factors Required for Virus Nuclear Entry. J Virol. 2015;89(17):9068–79. Epub 2015/06/26. 10.1128/JVI.00340-15 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref036] 36.Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, et al. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 2010;6(12):e1001220 Epub 2010/12/21. 10.1371/journal.ppat.1001220 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref037] 37.Bejarano DA, Peng K, Laketa V, Borner K, Jost KL, Lucic B, et al. HIV-1 nuclear import in macrophages is regulated by CPSF6-capsid interactions at the nuclear pore complex. Elife. 2019;8 Epub 2019/01/24. 10.7554/eLife.41800 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref038] 38.Achuthan V, Perreira JM, Sowd GA, Puray-Chavez M, McDougall WM, Paulucci-Holthauzen A, et al. Capsid-CPSF6 Interaction Licenses Nuclear HIV-1 Trafficking to Sites of Viral DNA Integration. Cell Host Microbe. 2018;24(3):392–404 e8. Epub 2018/09/04. 10.1016/j.chom.2018.08.002 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref039] 39.Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis. 2010;201(11):1686–96. Epub 2010/04/28. 10.1086/652420 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref040] 40.Hatziioannou T, Princiotta M, Piatak M Jr., Yuan F, Zhang F, Lifson JD, et al. Generation of simian-tropic HIV-1 by restriction factor evasion. Science. 2006;314(5796):95 Epub 2006/10/07. 10.1126/science.1130994 . [DOI] [PubMed] [Google Scholar]

[ppat.1008507.ref041] 41.Nisole S, Stoye JP, Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol. 2005;3(10):799–808. Epub 2005/09/22. 10.1038/nrmicro1248 . [DOI] [PubMed] [Google Scholar]

[ppat.1008507.ref042] 42.Yang Y, Brandariz-Nunez A, Fricke T, Ivanov DN, Sarnak Z, Diaz-Griffero F. Binding of the rhesus TRIM5alpha PRYSPRY domain to capsid is necessary but not sufficient for HIV-1 restriction. Virology. 2014;448:217–28. Epub 2013/12/10. 10.1016/j.virol.2013.10.012 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref043] 43.Sultana T, Mamede JI, Saito A, Ode H, Nohata K, Cohen R, et al. Multiple pathways to avoid IFN-beta sensitivity of HIV-1 by mutations in capsid. J Virol. 2019. Epub 2019/09/13. 10.1128/JVI.00986-19 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref044] 44.Hulme AE, Kelley Z, Okocha EA, Hope TJ. Identification of capsid mutations that alter the rate of HIV-1 uncoating in infected cells. J Virol. 2015;89(1):643–51. Epub 2014/10/24. 10.1128/JVI.03043-14 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref045] 45.Shah VB, Shi J, Hout DR, Oztop I, Krishnan L, Ahn J, et al. The host proteins transportin SR2/TNPO3 and cyclophilin A exert opposing effects on HIV-1 uncoating. J Virol. 2013;87(1):422–32. Epub 2012/10/26. 10.1128/JVI.07177-11 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref046] 46.McCauley SM, Kim K, Nowosielska A, Dauphin A, Yurkovetskiy L, Diehl WE, et al. Intron-containing RNA from the HIV-1 provirus activates type I interferon and inflammatory cytokines. Nat Commun. 2018;9(1):5305 Epub 2018/12/14. 10.1038/s41467-018-07753-2 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref047] 47.Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, Lascano J, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature. 2011;472(7343):361–5. Epub 2011/04/23. 10.1038/nature09976 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref048] 48.Yamashita M, Emerman M. Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J Virol. 2004;78(11):5670–8. Epub 2004/05/14. 10.1128/JVI.78.11.5670-5678.2004 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref049] 49.Henning MS, Dubose BN, Burse MJ, Aiken C, Yamashita M. In vivo functions of CPSF6 for HIV-1 as revealed by HIV-1 capsid evolution in HLA-B27-positive subjects. PLoS Pathog. 2014;10(1):e1003868 Epub 2014/01/15. 10.1371/journal.ppat.1003868 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref050] 50.Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 2003;114(1):21–31. Epub 2003/07/16. 10.1016/s0092-8674(03)00515-4 . [DOI] [PubMed] [Google Scholar]

[ppat.1008507.ref051] 51.Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5(5):512–7. Epub 1999/05/06. 10.1038/8394 . [DOI] [PubMed] [Google Scholar]

[ppat.1008507.ref052] 52.Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011;474(7353):658–61. Epub 2011/07/02. 10.1038/nature10195 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008507.ref053] 53.Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474(7353):654–7. Epub 2011/05/27. 10.1038/nature10117 . [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

TRIM34 restricts HIV-1 and SIV capsids in a TRIM5α-dependent manner

Molly Ohainle

Kyusik Kim

Sevnur Komurlu Keceli

Abby Felton

Ed Campbell

Jeremy Luban

Michael Emerman

Roles

Abstract

Author summary

Introduction

Results

HIV-CRISPR screening identifies TRIM34 as an inhibitor of the HIV-1 N74D capsid mutant

Fig 1. HIV-CRISPR screening identifies TRIM5α and TRIM34 as restriction factors for HIV-1 capsid mutant viruses, P90A and N74D.

TRIM34 inhibits N74D at a step before completion of reverse transcription

Fig 2. TRIM34 blocks HIV replication at the reverse transcription step in THP-1 and primary CD4+ T cells independent of IFN treatment.

TRIM34 restricts HIV-1 and SIV capsids independent of CPSF6 binding

Fig 3. TRIM34 inhibits a range of primate lentiviruses independent of CPSF6.

TRIM34 restriction requires TRIM5α

Fig 4. TRIM34 requires TRIM5α to restrict the N74D virus.

TRIM34 and TRIM5α complexes colocalize with N74D capsids

Fig 5. TRIM34 colocalizes more frequently with the restricted HIV-1 N74D capsid.

Discussion

TRIM34 is a capsid-targeting HIV-1 restriction factor

TRIM34 as a species barrier

TRIM34 restriction requires TRIM5α

Materials and methods

Cells and cell culture

Human blood

Ethics statement

Plasmids

Virus and lentivirus production

HIV-CRISPR screening & screen analysis

Transduction with lentiviral knockdown, knockout and overexpression vectors

Cas9/RNP electroporation

Editing analysis

Exogenous reverse transcriptase assay

Viral Infectivity assays

Flow cytometry

Luciferase assay

qPCR assay for HIV late reverse transcription products

Immunofluorescence microscopy

Supporting information

Acknowledgments

Data Availability

Funding Statement

References

Decision Letter 0

Susan R Ross

David T Evans

Roles

Author response to Decision Letter 0

Decision Letter 1

Susan R Ross

David T Evans

Roles

Acceptance letter

Susan R Ross

David T Evans

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases